Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32233956,tmax,"Pharmacokinetic parameters of d-amphetamine, a major active metabolite of LDX, were characterized: d-amphetamine exposure increased with LDX dose; mean tmax and t1/2, respectively, ranged from 4.00 to 4.23 hours and 7.18 to 8.46 hours.",Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233956/),h,4.00 to 4.23,490,DB00182,Amphetamine
,32233956,t1/2,"Pharmacokinetic parameters of d-amphetamine, a major active metabolite of LDX, were characterized: d-amphetamine exposure increased with LDX dose; mean tmax and t1/2, respectively, ranged from 4.00 to 4.23 hours and 7.18 to 8.46 hours.",Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32233956/),h,7.18 to 8.46,491,DB00182,Amphetamine
,23431065,maximum plasma d-amphetamine concentration,"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[ng] / [ml],44.2,2933,DB00182,Amphetamine
,23431065,maximum plasma d-amphetamine concentration,"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[ng] / [ml],47.7,2934,DB00182,Amphetamine
,23431065,maximum plasma d-amphetamine concentration,"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[ng] / [ml],53.4,2935,DB00182,Amphetamine
,23431065,area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)),"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[nghour] / [ml],915.0,2936,DB00182,Amphetamine
,23431065,area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)),"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[nghour] / [ml],1123.0,2937,DB00182,Amphetamine
,23431065,area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)),"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[nghour] / [ml],1325.0,2938,DB00182,Amphetamine
,23431065,time to reach peak plasma concentration,"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),h,4.5,2939,DB00182,Amphetamine
,23431065,time to reach peak plasma concentration,"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),h,3.5,2940,DB00182,Amphetamine
,23431065,time to reach peak plasma concentration,"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),h,5.5,2941,DB00182,Amphetamine
,23431065,maximum plasma d-amphetamine concentration,"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[ng] / [ml],51.0,2942,DB00182,Amphetamine
,23431065,maximum plasma d-amphetamine concentration,"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[ng] / [ml],50.2,2943,DB00182,Amphetamine
,23431065,maximum plasma d-amphetamine concentration,"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[ng] / [ml],64.3,2944,DB00182,Amphetamine
,23431065,AUC(0-inf),"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[h·ng] / [ml],1034.5,2945,DB00182,Amphetamine
,23431065,AUC(0-inf),"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[h·ng] / [ml],988.4,2946,DB00182,Amphetamine
,23431065,AUC(0-inf),"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),[h·ng] / [ml],1347.8,2947,DB00182,Amphetamine
,23431065,time to reach peak plasma concentration,"In the groups aged 55-64, 65-74, and ≥ 75 years, the mean maximum plasma d-amphetamine concentration in men was 44.2 ± 11.1, 47.7 ± 7.0, and 53.4 ± 19.4 ng/mL, respectively; area under the concentration time curve from time 0 extrapolated to infinity (AUC(0-inf)) was 915.0 ± 164.9, 1123.0 ± 227.0, and 1325.0 ± 464.4 nghour/mL; median time to reach peak plasma concentration was 4.5, 3.5, and 5.5 hours; in women, mean maximum plasma d-amphetamine concentration was 51.0 ± 6.7, 50.2 ± 6.8, and 64.3 ± 12.1 ng/mL, AUC(0-inf) was 1034.5 ± 154.6, 988.4 ± 80.5, and 1347.8 ± 198.9 ng hour/mL, and median time to reach peak plasma concentration was 3.5, 4.1, and 5.5 hours, respectively.","Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23431065/),h,4.1,2948,DB00182,Amphetamine
,29620701,tmax,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,6.0,3336,DB00182,Amphetamine
,29620701,tmax,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,6.3,3337,DB00182,Amphetamine
,29620701,t1/2,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,11,3338,DB00182,Amphetamine
,29620701,t1/2,"After oral administration, tmax values (coefficient of variation %) were 6.0 (17.0%) and 6.3 (16.3%) hours and t1/2 were 11 (24.6%) and 12 (25.4%) hours for 60 mg and 30 mg SR dexamphetamine, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),h,12,3339,DB00182,Amphetamine
,29620701,CSSmax,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],100,3340,DB00182,Amphetamine
,29620701,CSSmax,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],58.4,3341,DB00182,Amphetamine
,29620701,CSSmin,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],39.5,3342,DB00182,Amphetamine
,29620701,CSSmin,"At steady state, CSSmax values were reached at 100 (27.5%) ng/mL and 58.4 (14.4%) ng/mL, whereas CSSmin values were 39.5 (38.9%) ng/mL and 21.8 (19.8%) ng/mL for 60 mg and 30 mg, respectively.",Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29620701/),[ng] / [ml],21.8,3343,DB00182,Amphetamine
,25951660,total blood clearance,"Following intravenous administration of KUC-7322 (1 mg/kg), total blood clearance was 1.36 L/h/kg, suggesting that intrinsic hepatic clearance is the rate-limiting step in KUC-7322 excretion.","Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),[l] / [h·kg],1.36,5596,DB00182,Amphetamine
,25951660,half-life (t 1/2),"KUC-7322 levels rapidly decreased, with a half-life (t 1/2) of 0.42 to 1.37 h thereafter.","Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),h,0,5597,DB00182,Amphetamine
,25951660,half-life (t 1/2),"KUC-7322 levels rapidly decreased, with a half-life (t 1/2) of 0.42 to 1.37 h thereafter.","Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),h,1,5598,DB00182,Amphetamine
,25951660,bioavailability,The bioavailability of KUC-7322 was estimated to be 4%.,"Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),%,4,5599,DB00182,Amphetamine
,25951660,cumulative excretion,"The cumulative excretion of radioactivity in urine and feces were 28.7% and 68.3% of the dose, respectively, up to 120 h after administration.","Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),%,28.7,5600,DB00182,Amphetamine
,25951660,cumulative excretion,"The cumulative excretion of radioactivity in urine and feces were 28.7% and 68.3% of the dose, respectively, up to 120 h after administration.","Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25951660/),%,68.3,5601,DB00182,Amphetamine
,10654657,plasma half-life,"The plasma half-life of these compounds in children is approximately 5 h, with an onset of therapeutic action within a half-hour, and peak action at 1-3 h.",Clinical psychopharmacology of AD/HD: implications for animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10654657/),h,5,6446,DB00182,Amphetamine
,19571794,half-life,"Accordingly, to simulate the pharmacokinetic profile of a human METH binge exposure in rats, we used a computer-controlled, intravenous METH procedure (dynamic infusion, DI) to overcome species differences in METH pharmacokinetics and to replicate the human 12-h plasma METH half-life.",Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19571794/),h,12,6679,DB00182,Amphetamine
,9210980,clearance,"The clearance of D-OHMAP (93.5 mL min-1 kg-1) was slightly, but statistically significantly, greater than that of the L-enantiomer (83.9 mL min-1 kg-1).",p-Hydroxymethamphetamine enantiomer pharmacokinetics and metabolism in rats: absence of N-demethylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210980/),[ml] / [kg·min],93.5,7220,DB00182,Amphetamine
,9210980,clearance,"The clearance of D-OHMAP (93.5 mL min-1 kg-1) was slightly, but statistically significantly, greater than that of the L-enantiomer (83.9 mL min-1 kg-1).",p-Hydroxymethamphetamine enantiomer pharmacokinetics and metabolism in rats: absence of N-demethylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210980/),[ml] / [kg·min],83.9,7221,DB00182,Amphetamine
,9210980,steady-state volumes of distribution,"The steady-state volumes of distribution of L- and D-OHMAP were (mean +/- SD) 3.15 +/- 0.84 and 4.23 +/- 1.76 L kg-1, respectively.",p-Hydroxymethamphetamine enantiomer pharmacokinetics and metabolism in rats: absence of N-demethylation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210980/),[l] / [kg],3.15,7222,DB00182,Amphetamine
,9210980,steady-state volumes of distribution,"The steady-state volumes of distribution of L- and D-OHMAP were (mean +/- SD) 3.15 +/- 0.84 and 4.23 +/- 1.76 L kg-1, respectively.",p-Hydroxymethamphetamine enantiomer pharmacokinetics and metabolism in rats: absence of N-demethylation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210980/),[l] / [kg],4.23,7223,DB00182,Amphetamine
,30967099,Cmax,Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA).,"Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30967099/),[μg] / [l],229,7476,DB00182,Amphetamine
,30967099,Cmax,Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA).,"Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30967099/),[μg] / [l],3636,7477,DB00182,Amphetamine
,30967099,Cmax,Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA).,"Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30967099/),[μg] / [l],92,7478,DB00182,Amphetamine
,30967099,AUC0-∞,Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA).,"Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30967099/),[μg] / [l],3636,7479,DB00182,Amphetamine
,30967099,AUC0-∞,Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA).,"Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30967099/),[μg] / [l],1544,7480,DB00182,Amphetamine
,10565845,volume of distribution at steady state,"After the 1.0 mg/kg dose, the volume of distribution at steady state was 9.0 liters/kg, the total clearance was 126 ml/min/kg, and the average distribution and elimination half-lives were 9.2 and 63.0 min, respectively.",Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565845/),[l] / [kg],9.0,9699,DB00182,Amphetamine
,10565845,total clearance,"After the 1.0 mg/kg dose, the volume of distribution at steady state was 9.0 liters/kg, the total clearance was 126 ml/min/kg, and the average distribution and elimination half-lives were 9.2 and 63.0 min, respectively.",Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565845/),[ml] / [kg·min],126,9700,DB00182,Amphetamine
,10565845,distribution,"After the 1.0 mg/kg dose, the volume of distribution at steady state was 9.0 liters/kg, the total clearance was 126 ml/min/kg, and the average distribution and elimination half-lives were 9.2 and 63.0 min, respectively.",Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565845/),min,9.2,9701,DB00182,Amphetamine
,10565845,elimination half-lives,"After the 1.0 mg/kg dose, the volume of distribution at steady state was 9.0 liters/kg, the total clearance was 126 ml/min/kg, and the average distribution and elimination half-lives were 9.2 and 63.0 min, respectively.",Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565845/),min,63.0,9702,DB00182,Amphetamine
,10565845,T(1/2lambdaz),"(+)-AMP serum concentrations after the 1.0 mg/kg dose peaked from 10 to 30 min, and exhibited a T(1/2lambdaz) of 98.5 min.",Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565845/),min,98.5,9703,DB00182,Amphetamine
<,11417445,S/R ratio,Six extensive (mephenytoin S/R ratio < 0.3; EM) and six poor (mephenytoin S/R ratio > 0.8; PM) hydroxylators of S-mephenytoin ingested a single 10-mg oral dose of selegiline hydrochloride.,CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417445/),,0.3,12075,DB00182,Amphetamine
>,11417445,S/R ratio,Six extensive (mephenytoin S/R ratio < 0.3; EM) and six poor (mephenytoin S/R ratio > 0.8; PM) hydroxylators of S-mephenytoin ingested a single 10-mg oral dose of selegiline hydrochloride.,CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417445/),,0.8,12076,DB00182,Amphetamine
,22846898,initial detection time,"After FEN administration, both analytes could be detected in oral fluid of all volunteers with an initial detection time varying from 0.50 to 1.00 hour.",Fenproporex and amphetamine pharmacokinetics in oral fluid after controlled oral administration of fenproporex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22846898/),h,0.50 to 1.00,14644,DB00182,Amphetamine
,22846898,peak concentrations,FEN peak concentrations occurred between 1.00 and 1.50 hours after administration and were between 70.7 and 227.5 μg/L.,Fenproporex and amphetamine pharmacokinetics in oral fluid after controlled oral administration of fenproporex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22846898/),[μg] / [l],70.7 and 227.5,14645,DB00182,Amphetamine
,22846898,peak concentration,"For AMP, peak concentration occurred between 1.50 and 4.00 hours, reaching 33.0-150.9 μg/L.",Fenproporex and amphetamine pharmacokinetics in oral fluid after controlled oral administration of fenproporex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22846898/),[μg] / [l],33.0-150.9,14646,DB00182,Amphetamine
,10391421,weight,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22460,DB00182,Amphetamine
,10391421,weight-,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22461,DB00182,Amphetamine
,10391421,dose-normalized serum concentrations,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],47.26,22462,DB00182,Amphetamine
,10391421,dose-normalized serum concentrations,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[μg] / [l],39.02,22463,DB00182,Amphetamine
,10391421,clearance,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[l] / [kg],0.690,22464,DB00182,Amphetamine
,10391421,clearance,"Desipramine pharmacokinetic parameters were similar for both groups, including mean weight-corrected dose (3.66+/-1.36 mg/kg, desipramine; 3.66+/-1.09 mg/kg, desipramine-stimulants; p=0.97), weight- and dose-normalized serum concentrations (47.26+/-39.26 [microg/L]/[mg/kg], desipramine, 39.02+/-19.92 [microg/L]/[mg/kg], desipramine-stimulants; p=0.09), and clearance (0.690+/-0.913 [L/kg]/hr, desipramine; 0.613+/-0.514 [L/kg]/hr, desipramine-stimulants; p=0.499).",Absence of effect of stimulants on the phamacokinetics of desipramine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391421/),[l] / [kg],0.613,22465,DB00182,Amphetamine
,11471875,half-life,In one patient the 4-MTA concentration was determined in a series of plasma samples and this allowed a presumptive half-life of approximately 7 h to be estimated.,Analysis of 4-methylthioamphetamine in clinical specimens. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11471875/),h,7,23795,DB00182,Amphetamine
,24141857,Cmax,"After 2.5 mg/kg MDMA, mean MDMA Cmax was 164 ± 47.1 ng/ml, HHMA and HMMA were major metabolites, and <20% of MDMA was metabolized to MDA.","Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141857/),[ng] / [ml],164,26137,DB00182,Amphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.84,26928,DB00182,Amphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,3.05,26929,DB00182,Amphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.52,26930,DB00182,Amphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.75,26931,DB00182,Amphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.48,26932,DB00182,Amphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.65,26933,DB00182,Amphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.55,26934,DB00182,Amphetamine
,31809216,Tmax,"Mean ± standard deviation (SD) Tmax was comparable for AMP (d-AMP; l-AMP) following AR19 20 mg (2.84 ± 1.05; 3.05 ± 1.22) versus reference RA-AMPH (2.52 ± 0.75; 2.75 ± 1.00), and AR19 5 mg (2.48 ± 0.57; 2.65 ± 0.65) versus AR19 30 mg (2.55 ± 0.56; 2.72 ± 0.65).","Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.72,26935,DB00182,Amphetamine
,31809216,Tmax,Mean ± SD Tmax for AMP (d-AMP; l-AMP) was higher with intact capsule and meal (5.59 ± 1.57; 5.59 ± 1.59) versus fasted (2.85 ± 0.76; 2.97 ± 0.79).,"Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,5.59,26936,DB00182,Amphetamine
,31809216,Tmax,Mean ± SD Tmax for AMP (d-AMP; l-AMP) was higher with intact capsule and meal (5.59 ± 1.57; 5.59 ± 1.59) versus fasted (2.85 ± 0.76; 2.97 ± 0.79).,"Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,5.59,26937,DB00182,Amphetamine
,31809216,Tmax,Mean ± SD Tmax for AMP (d-AMP; l-AMP) was higher with intact capsule and meal (5.59 ± 1.57; 5.59 ± 1.59) versus fasted (2.85 ± 0.76; 2.97 ± 0.79).,"Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.85,26938,DB00182,Amphetamine
,31809216,Tmax,Mean ± SD Tmax for AMP (d-AMP; l-AMP) was higher with intact capsule and meal (5.59 ± 1.57; 5.59 ± 1.59) versus fasted (2.85 ± 0.76; 2.97 ± 0.79).,"Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: Bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809216/),,2.97,26939,DB00182,Amphetamine
,15740906,Recoveries,"Recoveries from urine and plasma were 80.0 and 98.9%, respectively and the limit of quantitation was 0.1 microg/mL at 233 nm.",Determination of modafinil in plasma and urine by reversed phase high-performance liquid-chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740906/),%,80.0,27113,DB00182,Amphetamine
,15740906,Recoveries,"Recoveries from urine and plasma were 80.0 and 98.9%, respectively and the limit of quantitation was 0.1 microg/mL at 233 nm.",Determination of modafinil in plasma and urine by reversed phase high-performance liquid-chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740906/),%,98.9,27114,DB00182,Amphetamine
,11327347,Peak concentrations,"Peak concentrations of 4-hydroxyclobenzorex ranged from 17,786 to 99,044 ng/mL.","Amphetamine, clobenzorex, and 4-hydroxyclobenzorex levels following multidose administration of clobenzorex. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327347/),[ng] / [ml],"17,786 to 99,044",27240,DB00182,Amphetamine
,11327347,LOD,"Most importantly, this study also found that all samples that contained amphetamine at > or =500 ng/mL also contained detectable amounts of this hydroxy metabolite (LOD 10 ng/mL), making it a valuable tool in differentiating use of clobenzorex from illicit amphetamine use.","Amphetamine, clobenzorex, and 4-hydroxyclobenzorex levels following multidose administration of clobenzorex. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327347/),[ng] / [ml],10,27241,DB00182,Amphetamine
,17080504,signal-to-noise ratio,The calibration curves prepared with 1-methyl-3-phenylpropylamine (MPPA) as an internal standard showed good linearity (r = 0.999) with 0.36-0.83 ng/mL detection limit at a signal-to-noise ratio of 3.,"A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080504/),,3,29104,DB00182,Amphetamine
,17080504,C(max),"The pharmacokinetic parameters for MDMA and MDA obtained by triplicate measurements were 426 +/- 23 and 39 +/- 6 ng/mL (C(max)), 20 +/- 5 and 100 +/- 10 min (T(max)), respectively.","A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080504/),[ng] / [ml],426,29105,DB00182,Amphetamine
,17080504,C(max),"The pharmacokinetic parameters for MDMA and MDA obtained by triplicate measurements were 426 +/- 23 and 39 +/- 6 ng/mL (C(max)), 20 +/- 5 and 100 +/- 10 min (T(max)), respectively.","A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080504/),[ng] / [ml],39,29106,DB00182,Amphetamine
,17080504,T(max),"The pharmacokinetic parameters for MDMA and MDA obtained by triplicate measurements were 426 +/- 23 and 39 +/- 6 ng/mL (C(max)), 20 +/- 5 and 100 +/- 10 min (T(max)), respectively.","A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080504/),min,20,29107,DB00182,Amphetamine
,17080504,T(max),"The pharmacokinetic parameters for MDMA and MDA obtained by triplicate measurements were 426 +/- 23 and 39 +/- 6 ng/mL (C(max)), 20 +/- 5 and 100 +/- 10 min (T(max)), respectively.","A simple and sensitive HPLC-fluorescence method for quantification of MDMA and MDA in blood with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl) as a label. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17080504/),min,100,29108,DB00182,Amphetamine
,8104133,bioavailability,The bioavailability of smoked methamphetamine was 90.3 +/- 10.4%.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),%,90.3,29520,DB00182,Amphetamine
,8104133,Oral bioavailability,(Oral bioavailability calculated from this study and a previous one was 67.2 +/- 3.1%).,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),%,67.2,29521,DB00182,Amphetamine
,8104133,plasma half-life,The geometric mean plasma half-life was 11.1 hr for smoked methamphetamine and 12.2 hr for the intravenous drug.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),h,11.1,29522,DB00182,Amphetamine
,8104133,plasma half-life,The geometric mean plasma half-life was 11.1 hr for smoked methamphetamine and 12.2 hr for the intravenous drug.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),h,12.2,29523,DB00182,Amphetamine
,8104133,volume of distribution in the elimination phase,The volume of distribution in the elimination phase was 3.24 +/- 0.36 liter/kg for the smoked dose and 3.73 +/- 0.59 liter/kg for the intravenous dose.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),[l] / [kg],3.24,29524,DB00182,Amphetamine
,8104133,volume of distribution in the elimination phase,The volume of distribution in the elimination phase was 3.24 +/- 0.36 liter/kg for the smoked dose and 3.73 +/- 0.59 liter/kg for the intravenous dose.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),[l] / [kg],3.73,29525,DB00182,Amphetamine
,8104133,mean residence times,The mean residence times were 11.5 +/- 0.5 hr and 11.3 +/- 1.74 hr for the two routes.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),h,11.5,29526,DB00182,Amphetamine
,8104133,mean residence times,The mean residence times were 11.5 +/- 0.5 hr and 11.3 +/- 1.74 hr for the two routes.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),h,11.3,29527,DB00182,Amphetamine
,14993256,equilibrium dissociation constant (K(d)),"Intravenous administration of a 1 g/kg dose of the lower affinity [antibody equilibrium dissociation constant (K(d)) = 250 nM] monoclonal antibody (mAb) designated mAb6H8, 1 day before the start of several daily 2-h self-administration sessions produced effects that depended on the dose of (+)-methamphetamine.",Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14993256/),nM,250,30452,DB00182,Amphetamine
,14993256,K(d),"Intravenous administration of a 1 or a 0.6 g/kg dose of a higher affinity (K(d) = 11 nM) mAb designated mAb6H4, 24 h before the first of several self-administration sessions, produced very similar effects to the lower affinity mAb, despite the more than 20-fold greater affinity for (+)-methamphetamine.",Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14993256/),nM,11,30453,DB00182,Amphetamine
,8074957,tumor uptake,"In pulmonary cancer, the tumor uptake of the administered dose without a tissue attenuation correction (% uptake) of 123I-IMP at 1-2 min after injection was 14.7 +/- 5.7% (s.d.).",Intra-arterial infusion of N-isopropyl-p[123I]iodoamphetamine for assessing effective blood supply to pulmonary and hepatic neoplasms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074957/),%,14.7,35500,DB00182,Amphetamine
,8074957,tumor to normal tissue ratio,The tumor to normal tissue ratio was 2.1 +/- 0.7 in hepatocellular carcinoma and 1.4 +/- 0.7 in metastatic tumors.,Intra-arterial infusion of N-isopropyl-p[123I]iodoamphetamine for assessing effective blood supply to pulmonary and hepatic neoplasms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074957/),,2.1,35501,DB00182,Amphetamine
,8074957,tumor to normal tissue ratio,The tumor to normal tissue ratio was 2.1 +/- 0.7 in hepatocellular carcinoma and 1.4 +/- 0.7 in metastatic tumors.,Intra-arterial infusion of N-isopropyl-p[123I]iodoamphetamine for assessing effective blood supply to pulmonary and hepatic neoplasms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8074957/),,1.4,35502,DB00182,Amphetamine
,19820270,exposure,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],45.0,38540,DB00182,Amphetamine
,19820270,exposure,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],713.0,38541,DB00182,Amphetamine
,19820270,exposure,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],761.6,38542,DB00182,Amphetamine
,19820270,Cmax,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],46.3,38543,DB00182,Amphetamine
,19820270,Cmax,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],761.6,38544,DB00182,Amphetamine
,19820270,AUCinf,"For LDX monotherapy, d-amphetamine mean (SD) exposure was 45.0 (13.97) ng/mL and 713.0 (134.75) ng . h/mL; when coadministered with omeprazole it was 46.3 (9.71) ng/mL and 761.6 (191.13) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],761.6,38545,DB00182,Amphetamine
,19820270,Tmax,The median Tmax was 3 hours with and without omeprazole.,Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),h,3,38546,DB00182,Amphetamine
,19820270,exposure,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],36.6,38547,DB00182,Amphetamine
,19820270,exposure,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],640.8,38548,DB00182,Amphetamine
,19820270,exposure,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],643.9,38549,DB00182,Amphetamine
,19820270,Cmax,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[ng] / [ml],38.1,38550,DB00182,Amphetamine
,19820270,Cmax,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],643.9,38551,DB00182,Amphetamine
,19820270,AUCinf,"For MAS XR monotherapy, total amphetamine mean (SD) exposure was 36.6 (9.19) ng/mL and 640.8 (95.66) ng . h/mL; when coadministered with omeprazole it was 38.1 (7.35) ng/mL and 643.9 (143.16) ng . h/mL, for Cmax and AUCinf, respectively.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),[h·ng] / [ml],643.9,38552,DB00182,Amphetamine
,19820270,Tmax,"The median Tmax was 5 hours and 2.75 hours without and with omeprazole, respectively; 57.1% to 61.9% of subjects receiving MAS XR and 25% receiving LDX showed an earlier (>or= 1 hour) Tmax with omeprazole.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),h,5,38553,DB00182,Amphetamine
,19820270,Tmax,"The median Tmax was 5 hours and 2.75 hours without and with omeprazole, respectively; 57.1% to 61.9% of subjects receiving MAS XR and 25% receiving LDX showed an earlier (>or= 1 hour) Tmax with omeprazole.",Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820270/),h,2.75,38554,DB00182,Amphetamine
>,15319342,(R)/(S) ratios,"(R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),,1,39088,DB00182,Amphetamine
<,15319342,(R)/(S) ratios,"(R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),,1,39089,DB00182,Amphetamine
,15319342,elimination half-life,"The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),h,4.8,39090,DB00182,Amphetamine
,15319342,half-life,"The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),h,14.8,39091,DB00182,Amphetamine
>,26395866,R/S ratios,"R/S ratios were >1 for all analytes after 24 hours, independent of the initial chiral preference.","Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26395866/),,1,39803,DB00182,Amphetamine
,20173084,time to C(max),Median time to C(max) ranged from 4 to 6 hours for d-amphetamine and 1.0 to 1.5 hours for lisdexamfetamine dimesylate.,"Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173084/),h,4 to 6,40695,DB00182,Amphetamine
,20173084,time to C(max),Median time to C(max) ranged from 4 to 6 hours for d-amphetamine and 1.0 to 1.5 hours for lisdexamfetamine dimesylate.,"Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20173084/),h,1.0 to 1.5,40696,DB00182,Amphetamine
,14628189,area-under-the curve (AUC(0- infinity)),Mean [SD] area-under-the curve (AUC(0- infinity)) values following Zydis Selegiline 10 mg (5.85 [7.31] ng.h/mL) were approximately five times higher than those following conventional selegiline tablets 10 mg (1.16 [1.05] ng.h/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[h·ng] / [ml],5.85,41070,DB00182,Amphetamine
,14628189,area-under-the curve (AUC(0- infinity)),Mean [SD] area-under-the curve (AUC(0- infinity)) values following Zydis Selegiline 10 mg (5.85 [7.31] ng.h/mL) were approximately five times higher than those following conventional selegiline tablets 10 mg (1.16 [1.05] ng.h/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[h·ng] / [ml],1.16,41071,DB00182,Amphetamine
,14628189,C(max),The C(max) of selegiline was similar following administration of Zydis Selegiline 1.25 mg (1.52 ng/mL) or conventional selegiline tablets 10 mg (1.14 mg/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],1.52,41072,DB00182,Amphetamine
,14628189,C(max),The C(max) of selegiline was similar following administration of Zydis Selegiline 1.25 mg (1.52 ng/mL) or conventional selegiline tablets 10 mg (1.14 mg/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[mg] / [ml],1.14,41073,DB00182,Amphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],1.19,41074,DB00182,Amphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],0.34,41075,DB00182,Amphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],0.93,41076,DB00182,Amphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],18.37,41077,DB00182,Amphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],3.60,41078,DB00182,Amphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],12.92,41079,DB00182,Amphetamine
,14628189,excretion,Mean daily PEA excretion was similar following Zydis Selegiline 1.25 mg and conventional selegiline tablets 10 mg (13.0 microg versus 17.6 microg).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),μg,13.0,41080,DB00182,Amphetamine
,14628189,excretion,Mean daily PEA excretion was similar following Zydis Selegiline 1.25 mg and conventional selegiline tablets 10 mg (13.0 microg versus 17.6 microg).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),μg,17.6,41081,DB00182,Amphetamine
,8208060,t1/2,N-OH MDA disappeared from the plasma at an apparent first-order rate with a t1/2 of 36.3 +/- 8.4 min.,"The pharmacokinetics and liver metabolism of N-hydroxy-3,4-methylenedioxyamphetamine (N-OH MDA) in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8208060/),min,36.3,41116,DB00182,Amphetamine
,8208060,t1/2,"With rapid blood sampling, a t1/2 of 0.86 +/- 0.12 min was observed for N-OH MDA.","The pharmacokinetics and liver metabolism of N-hydroxy-3,4-methylenedioxyamphetamine (N-OH MDA) in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8208060/),min,0.86,41117,DB00182,Amphetamine
,8208060,total body clearance,A total body clearance of 9.09 +/- 2.06 L/hr/kg and a volume of distribution of 0.184 +/- 0.022 L/kg were noted.,"The pharmacokinetics and liver metabolism of N-hydroxy-3,4-methylenedioxyamphetamine (N-OH MDA) in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8208060/),[l] / [h·kg],9.09,41118,DB00182,Amphetamine
,8208060,volume of distribution,A total body clearance of 9.09 +/- 2.06 L/hr/kg and a volume of distribution of 0.184 +/- 0.022 L/kg were noted.,"The pharmacokinetics and liver metabolism of N-hydroxy-3,4-methylenedioxyamphetamine (N-OH MDA) in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8208060/),[l] / [kg],0.184,41119,DB00182,Amphetamine
,8208060,t1/2,The MDA t1/2 after N-OH MDA dosing was 1.68 +/- 0.29 hours with peak plasma concentrations at 8 min.,"The pharmacokinetics and liver metabolism of N-hydroxy-3,4-methylenedioxyamphetamine (N-OH MDA) in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8208060/),h,1.68,41120,DB00182,Amphetamine
,3984382,biological half-life of the alpha phase (t alpha 1/2),"The biological half-life of the alpha phase (t alpha 1/2) was 6.8 +/- 2.0 min, and that of the beta phase (t beta 1/2) was 11.3 +/- 0.8 h.","Distribution and excretion of methamphetamine and its metabolites in rats. Time-course of concentrations in blood and bile, and distribution after intravenous administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3984382/),min,6.8,42756,DB00182,Amphetamine
,3984382,t beta 1/2),"The biological half-life of the alpha phase (t alpha 1/2) was 6.8 +/- 2.0 min, and that of the beta phase (t beta 1/2) was 11.3 +/- 0.8 h.","Distribution and excretion of methamphetamine and its metabolites in rats. Time-course of concentrations in blood and bile, and distribution after intravenous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3984382/),h,11.3,42757,DB00182,Amphetamine
,18455783,time to maximum concentration,The time to maximum concentration for METH and AMP following i.m. administration was 0.3 h.,Bioavailability of (+)-methamphetamine in the pigeon following an intramuscular dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18455783/),h,0.3,43633,DB00182,Amphetamine
,18991468,time to reach maximum plasma drug concentration (t(max)),"For intact lisdexamfetamine dimesylate, the median time to reach maximum plasma drug concentration (t(max)) was 1.00 hour, and the mean maximum plasma drug concentration (C(max)) was 58.2 +/- 28.1 ng/mL.","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),h,1.00,43787,DB00182,Amphetamine
,18991468,maximum plasma drug concentration (C(max)),"For intact lisdexamfetamine dimesylate, the median time to reach maximum plasma drug concentration (t(max)) was 1.00 hour, and the mean maximum plasma drug concentration (C(max)) was 58.2 +/- 28.1 ng/mL.","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),[ng] / [ml],58.2,43788,DB00182,Amphetamine
,18991468,area under the drug concentration-time curve from time 0 to infinity [AUC(infinity)],"Intact lisdexamfetamine dimesylate exhibited modest systemic exposure (area under the drug concentration-time curve from time 0 to infinity [AUC(infinity)] 67.04 +/- 18.94 ng . h/mL), and rapid elimination (mean apparent terminal elimination half-life [t((1/2)beta)] 0.47 hours).","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),[h·ng] / [ml],67.04,43789,DB00182,Amphetamine
,18991468,apparent terminal elimination half-life [t((1/2)beta)],"Intact lisdexamfetamine dimesylate exhibited modest systemic exposure (area under the drug concentration-time curve from time 0 to infinity [AUC(infinity)] 67.04 +/- 18.94 ng . h/mL), and rapid elimination (mean apparent terminal elimination half-life [t((1/2)beta)] 0.47 hours).","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),h,0.47,43790,DB00182,Amphetamine
,18991468,t(max),"For d-amphetamine, the median t(max) was 3.00 hours, and the mean C(max) was 80.3 +/- 11.8 ng/mL.","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),h,3.00,43791,DB00182,Amphetamine
,18991468,C(max),"For d-amphetamine, the median t(max) was 3.00 hours, and the mean C(max) was 80.3 +/- 11.8 ng/mL.","Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),[ng] / [ml],80.3,43792,DB00182,Amphetamine
,18991468,AUC(infinity),The AUC(infinity) of d-amphetamine was 1342 +/- 216.9 ng .,"Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),ng,1342,43793,DB00182,Amphetamine
,18991468,t((1/2)beta),The t((1/2)beta) of d-amphetamine was 10.39 hours.,"Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18991468/),h,10.39,43794,DB00182,Amphetamine
,33031519,apparent elimination half-lives (t1/2),"With mean 12.9 (8.3-16.1) hours, apparent elimination half-lives (t1/2) were significantly (p < 0.01) longer for (R)-4-FA than for (S)-4-FA (6.0 hours; range 4.4-10.2 hours) and independent of the dose given.",Chiral Serum Pharmacokinetics of 4-Fluoroamphetamine after Controlled Oral Administration: Can (R)/(S) Concentration Ratios Help in Interpreting Forensic Cases? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33031519/),h,6.0,43796,DB00182,Amphetamine
,33031519,maximum ratios,"Over time, (R)/(S)-concentration-ratios were linearly increasing in all subjects to maximum ratios of 2.00 (1.08-2.77) in the last samples (after 12 hours).",Chiral Serum Pharmacokinetics of 4-Fluoroamphetamine after Controlled Oral Administration: Can (R)/(S) Concentration Ratios Help in Interpreting Forensic Cases? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33031519/),,2.00,43797,DB00182,Amphetamine
,33031519,(R)/(S)-ratio,"The slopes of the (R)/(S)-ratio exhibited marked inter-individual differences (0.023 to 0.157 h-1, mean 0.095 h-1).",Chiral Serum Pharmacokinetics of 4-Fluoroamphetamine after Controlled Oral Administration: Can (R)/(S) Concentration Ratios Help in Interpreting Forensic Cases? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33031519/),1/[h],0.095,43798,DB00182,Amphetamine
higher,33031519,Ratios,Ratios higher than 1.60 only appeared earliest after a minimum of 6 hours and therefore suggest the absence of acute drug effects.,Chiral Serum Pharmacokinetics of 4-Fluoroamphetamine after Controlled Oral Administration: Can (R)/(S) Concentration Ratios Help in Interpreting Forensic Cases? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33031519/),,1.60,43799,DB00182,Amphetamine
,17452029,flow rate,"Reverse-phase HPLC separation was accomplished on a Zorbax SB-C18 column (100 mm x 3.0 mm, 3.5 microm) with a mobile phase composed of methanol-water-formic acid (65:35:0.5, v/v/v) at a flow rate of 0.2 mL/min.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),[ml] / [min],0.2,43873,DB00182,Amphetamine
,17452029,total run time,The method had a chromatographic total run time of 5 min.,Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),min,5,43874,DB00182,Amphetamine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,136.0,43875,DB00182,Amphetamine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,91.0,43876,DB00182,Amphetamine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,256.0,43877,DB00182,Amphetamine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,166.1,43878,DB00182,Amphetamine
,18089653,Limits of quantification,"Limits of quantification were 1.0 microg/L for MDA and 2.5 microg/L for MDEA, MDMA, HMMA, and HMA.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),[μg] / [l],1.0,44209,DB00182,Amphetamine
,18089653,Limits of quantification,"Limits of quantification were 1.0 microg/L for MDA and 2.5 microg/L for MDEA, MDMA, HMMA, and HMA.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),[μg] / [l],2.5,44210,DB00182,Amphetamine
> or =,18089653,overall extraction efficiencies,"At 3 concentrations spanning the linear dynamic range of the assay, mean overall extraction efficiencies from plasma were > or =85% for all compounds of interest.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,85,44211,DB00182,Amphetamine
,18089653,Recoveries,"Recoveries were 85.6% to 107.2% of target, and intra- and interassay imprecision (CV) was <8.5% for all drugs at 3 concentrations within the range of the assay.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,85.6,44212,DB00182,Amphetamine
,18089653,Recoveries,"Recoveries were 85.6% to 107.2% of target, and intra- and interassay imprecision (CV) was <8.5% for all drugs at 3 concentrations within the range of the assay.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,107.2,44213,DB00182,Amphetamine
,26475522,minimum effective dose,"A potent and selective PAM, 1-(2-(phenoxymethyl)-6,7-dihydropyrazolo[1,5-a]pyrimidin-4(5H)-yl)ethanone (9a, VU0462807), was identified with superior solubility and efficacy in the acute amphetamine-induced hyperlocomotion (AHL) rat model with a minimum effective dose of 3mg/kg.","Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26475522/),[mg] / [kg],3,45646,DB00182,Amphetamine
,11043667,detection limit,Clobenzorex itself has been detected for as long as 29 h postdose using a detection limit of 1 ng/mL.,Differentiation of clobenzorex use from amphetamine abuse using the metabolite 4-hydroxyclobenzorex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043667/),[ng] / [ml],1,47824,DB00182,Amphetamine
,11043667,Peak concentrations,"Peak concentrations of 4-hydroxyclobenzorex were found at approximately 1:30-5:00 h postdose and ranged from approximately 5705 to 88,410 ng/mL.",Differentiation of clobenzorex use from amphetamine abuse using the metabolite 4-hydroxyclobenzorex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043667/),[ng] / [ml],"5705 to 88,410",47825,DB00182,Amphetamine
,11043667,LOD,"Most importantly, however, all samples that contained amphetamine at > or = 500 ng/mL also contained detectable amounts of this hydroxy metabolite (LOD 10 ng/mL), making it a valuable tool in differentiating use of clobenzorex from illicit amphetamine use.",Differentiation of clobenzorex use from amphetamine abuse using the metabolite 4-hydroxyclobenzorex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11043667/),[ng] / [ml],10,47826,DB00182,Amphetamine
,18285619,t(max),The t(max) of d-amphetamine and intact lisdexamfetamine was similar when taken in solution or in the fasted state but was about 1 hour longer when taken with food.,"Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18285619/),h,1,49318,DB00182,Amphetamine
,31058136,Extra,"Extraction recoveries ranged from 48.6 to 105.4% with coefficients of variation (CV) ≤ 13.7%, and matrix effects ranged from 45.4 to 104.1% with CV ≤ 10.3%.","Simultaneous Determination of Selegiline, Desmethylselegiline, R/S-methamphetamine, and R/S-amphetamine on Dried Urine Spots by LC/MS/MS: Application to a Pharmacokinetic Study in Urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058136/),%,48.6 to 105.4,52709,DB00182,Amphetamine
,27935735,"area under the plasma concentration versus time curve, AUC","LDX levels peaked at 1.5 hours after administration (Tmax) and then rapidly declined (levels were negligible at 6 hours and area under the plasma concentration versus time curve, AUC = 45.9, Cmax = 25.0, and half-life [t1/2] = 0.5 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),,45.9,52816,DB00182,Amphetamine
,27935735,Cmax,"LDX levels peaked at 1.5 hours after administration (Tmax) and then rapidly declined (levels were negligible at 6 hours and area under the plasma concentration versus time curve, AUC = 45.9, Cmax = 25.0, and half-life [t1/2] = 0.5 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,25.0,52817,DB00182,Amphetamine
,27935735,half-life [t1/2],"LDX levels peaked at 1.5 hours after administration (Tmax) and then rapidly declined (levels were negligible at 6 hours and area under the plasma concentration versus time curve, AUC = 45.9, Cmax = 25.0, and half-life [t1/2] = 0.5 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,0.5,52818,DB00182,Amphetamine
,27935735,Tmax),"Levels of d-amphetamine peaked at (Tmax) 4.4 hours and then slowly declined (AUC = 641.6, Cmax = 67.9, and t1/2 = 17.0 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,4.4,52819,DB00182,Amphetamine
,27935735,AUC,"Levels of d-amphetamine peaked at (Tmax) 4.4 hours and then slowly declined (AUC = 641.6, Cmax = 67.9, and t1/2 = 17.0 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,641.6,52820,DB00182,Amphetamine
,27935735,Cmax,"Levels of d-amphetamine peaked at (Tmax) 4.4 hours and then slowly declined (AUC = 641.6, Cmax = 67.9, and t1/2 = 17.0 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,67.9,52821,DB00182,Amphetamine
,27935735,t1/2,"Levels of d-amphetamine peaked at (Tmax) 4.4 hours and then slowly declined (AUC = 641.6, Cmax = 67.9, and t1/2 = 17.0 hours).",Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27935735/),h,17.0,52822,DB00182,Amphetamine
,31964449,Tmax,"For d- and l-amphetamine when the tablet is swallowed whole, Tmax was 5.00 hours (with a range of 2.00-9.00 hours).",Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31964449/),h,5.00,54649,DB00182,Amphetamine
,31964449,Tmax,"For d- and l-amphetamine when the tablet has been chewed, Tmax was 5.00 hours (with a range of 3.00-7.00 hours).",Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31964449/),h,5.00,54650,DB00182,Amphetamine
,7985801,concentrations,"Basal whole brain and striatal concentrations were 0.584 +/- 0.243 ng/g wet wt (n = 3) and 2.89 +/- 1.03 ng/g wet wt (n = 4), respectively.",The measurement of beta-phenylethylamine in human plasma and rat brain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985801/),[ng] / [g·wet·wt],2.89,54677,DB00182,Amphetamine
,14520168,terminal half life time,"The median terminal half life time was 14.3 hours (inter quartile range, IQR: 11.9-6.9), 13.1 (IQR: 10.8-15.9) and 14.0 (IQR: 7.4-16.4) in the 2.5 mg, 5 mg, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),h,14.3,56377,DB00182,Amphetamine
,14520168,terminal half life time,"The median terminal half life time was 14.3 hours (inter quartile range, IQR: 11.9-6.9), 13.1 (IQR: 10.8-15.9) and 14.0 (IQR: 7.4-16.4) in the 2.5 mg, 5 mg, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),h,13.1,56378,DB00182,Amphetamine
,14520168,terminal half life time,"The median terminal half life time was 14.3 hours (inter quartile range, IQR: 11.9-6.9), 13.1 (IQR: 10.8-15.9) and 14.0 (IQR: 7.4-16.4) in the 2.5 mg, 5 mg, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),h,14.0,56379,DB00182,Amphetamine
,14520168,maximal plasma concentration (Cmax),"The median maximal plasma concentration (Cmax) was 6.6 ng/mL (IQR: 5.1-7.0), 11.6 (IQR: 7.8-12.8), and 16.9 (IQR: 14.9-20.2) in the 2.5 mg, 5 mg, and the 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),[ng] / [ml],6.6,56380,DB00182,Amphetamine
,14520168,maximal plasma concentration (Cmax),"The median maximal plasma concentration (Cmax) was 6.6 ng/mL (IQR: 5.1-7.0), 11.6 (IQR: 7.8-12.8), and 16.9 (IQR: 14.9-20.2) in the 2.5 mg, 5 mg, and the 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),[ng] / [ml],11.6,56381,DB00182,Amphetamine
,14520168,maximal plasma concentration (Cmax),"The median maximal plasma concentration (Cmax) was 6.6 ng/mL (IQR: 5.1-7.0), 11.6 (IQR: 7.8-12.8), and 16.9 (IQR: 14.9-20.2) in the 2.5 mg, 5 mg, and the 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),[ng] / [ml],16.9,56382,DB00182,Amphetamine
,14520168,time to Cmax (Tmax),"The median time to Cmax (Tmax) was 1.83 hours (IQR: 1.79-3.94), 2.59 (IQR: 1.32-3.83), and 3.86 (IQR: 1.82-5.77) in the 2.5, 5, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),h,1.83,56383,DB00182,Amphetamine
,14520168,time to Cmax (Tmax),"The median time to Cmax (Tmax) was 1.83 hours (IQR: 1.79-3.94), 2.59 (IQR: 1.32-3.83), and 3.86 (IQR: 1.82-5.77) in the 2.5, 5, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),,2.59,56384,DB00182,Amphetamine
,14520168,time to Cmax (Tmax),"The median time to Cmax (Tmax) was 1.83 hours (IQR: 1.79-3.94), 2.59 (IQR: 1.32-3.83), and 3.86 (IQR: 1.82-5.77) in the 2.5, 5, and 10 mg groups, respectively.",Pharmacokinetics of dexamphetamine in acute stroke. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520168/),,3.86,56385,DB00182,Amphetamine
,17825539,EC(50),"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],237,58611,DB00182,Amphetamine
,17825539,EC(50),"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],174,58612,DB00182,Amphetamine
,17825539,EC(50),"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],100,58613,DB00182,Amphetamine
,17825539,P,"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],237,58614,DB00182,Amphetamine
,17825539,P,"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],174,58615,DB00182,Amphetamine
,17825539,P,"For EXC, EC(50) values for the cumulative probabilities P(Y<1), P(Y<2), P(Y<3) were 237+/-39, 174+/-28 and 100+/-20 ng ml(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17825539/),[ng] / [ml],100,58616,DB00182,Amphetamine
,21871156,maximum plasma concentrations (C(max)),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [l],916- 1363,60715,DB00182,Amphetamine
,21871156,maximum plasma concentrations (C(max)),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [l],1833-3546,60716,DB00182,Amphetamine
,21871156,maximum plasma concentrations (C(max)),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [l],5979-7948,60717,DB00182,Amphetamine
,21871156,C(max),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [kg],"6673-14,869",60718,DB00182,Amphetamine
,21871156,C(max),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [kg],"23,428-29,433",60719,DB00182,Amphetamine
,21871156,C(max),"MDMA maximum plasma concentrations (C(max)) for both strains were 916- 1363, 1833-3546, and 5979-7948 μg/L, whereas brain C(max) were 6673-14,869, 23,428-29,433, and 52,735-66,525 μg/kg after 10, 20, or 40 mg/kg MDMA, respectively.","(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871156/),[μg] / [kg],"52,735-66,525",60720,DB00182,Amphetamine
,33298381,recoveries,The recoveries of MET and EPD from the mice plasma and brain ranged from 108.5 to 112.1%.,Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),%,108.5 to 112.1,62129,DB00182,Amphetamine
,33298381,Cmax,The results exhibited that the Cmax and Tmax of MET in mice plasma was 517.1 ng/mL and 15 min as compared to 3.6 ng/mL and 2 h of EPD.,Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),[ng] / [ml],517.1,62130,DB00182,Amphetamine
,33298381,Cmax,The results exhibited that the Cmax and Tmax of MET in mice plasma was 517.1 ng/mL and 15 min as compared to 3.6 ng/mL and 2 h of EPD.,Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),[ng] / [ml],3.6,62131,DB00182,Amphetamine
,33298381,Tmax,The results exhibited that the Cmax and Tmax of MET in mice plasma was 517.1 ng/mL and 15 min as compared to 3.6 ng/mL and 2 h of EPD.,Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),min,15,62132,DB00182,Amphetamine
,33298381,Tmax,The results exhibited that the Cmax and Tmax of MET in mice plasma was 517.1 ng/mL and 15 min as compared to 3.6 ng/mL and 2 h of EPD.,Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),h,2,62133,DB00182,Amphetamine
,33298381,Cmax,"Moreover, MET rapidly passed the blood brain barrier with Cmax of 1444.5 ng/mL achieved at 15 min, whereas, EPD monitored Cmax of 43.6 ng/mL at 4 h in mice brain.",Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),[ng] / [ml],1444.5,62134,DB00182,Amphetamine
,33298381,Cmax,"Moreover, MET rapidly passed the blood brain barrier with Cmax of 1444.5 ng/mL achieved at 15 min, whereas, EPD monitored Cmax of 43.6 ng/mL at 4 h in mice brain.",Development and validation of GC-MS method for determination of methcathinone and its main metabolite in mice plasma and brain tissue after SPE: Pharmacokinetic and distribution study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33298381/),[ng] / [ml],43.6,62135,DB00182,Amphetamine
,2083146,half-life,The average half-life (+/- SD) for all dosing groups was 2.5 +/- 0.8 h for (-)-(R)-MDMA and 2.2 +/- 0.8 h for (+)-(S)-MDMA.,"Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),h,2.5,63431,DB00182,Amphetamine
,2083146,half-life,The average half-life (+/- SD) for all dosing groups was 2.5 +/- 0.8 h for (-)-(R)-MDMA and 2.2 +/- 0.8 h for (+)-(S)-MDMA.,"Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),h,2.2,63432,DB00182,Amphetamine
,2083146,AUC S/R ratios,"The mean (+/- SD) AUC S/R ratios of MDMA and MDA were 0.70 +/- 0.05 and 3.1 +/- 0.8, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,0.70,63433,DB00182,Amphetamine
,2083146,AUC S/R ratios,"The mean (+/- SD) AUC S/R ratios of MDMA and MDA were 0.70 +/- 0.05 and 3.1 +/- 0.8, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,3.1,63434,DB00182,Amphetamine
,2083146,percent dose excreted,"Following a 20 mg/kg dose of racemic MDMA iv the mean (+/- SD) of the percent dose excreted as (-)-(R)-MDMA, (+)-(S)-MDMA, (-)-(R)-MDA, and (+)-(S)-MDA were 20 +/- 10, 12 +/- 6, 3 +/- 1, and 6 +/- 2, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,20,63435,DB00182,Amphetamine
,2083146,percent dose excreted,"Following a 20 mg/kg dose of racemic MDMA iv the mean (+/- SD) of the percent dose excreted as (-)-(R)-MDMA, (+)-(S)-MDMA, (-)-(R)-MDA, and (+)-(S)-MDA were 20 +/- 10, 12 +/- 6, 3 +/- 1, and 6 +/- 2, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,12,63436,DB00182,Amphetamine
,2083146,percent dose excreted,"Following a 20 mg/kg dose of racemic MDMA iv the mean (+/- SD) of the percent dose excreted as (-)-(R)-MDMA, (+)-(S)-MDMA, (-)-(R)-MDA, and (+)-(S)-MDA were 20 +/- 10, 12 +/- 6, 3 +/- 1, and 6 +/- 2, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,3,63437,DB00182,Amphetamine
,2083146,percent dose excreted,"Following a 20 mg/kg dose of racemic MDMA iv the mean (+/- SD) of the percent dose excreted as (-)-(R)-MDMA, (+)-(S)-MDMA, (-)-(R)-MDA, and (+)-(S)-MDA were 20 +/- 10, 12 +/- 6, 3 +/- 1, and 6 +/- 2, respectively.","Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2083146/),,6,63438,DB00182,Amphetamine
,22832282,T(max),A pharmacokinetic study found a T(max) of 0.25 h and a C(max) of 1206 ng/ml after 5.6 mg/kg 4-MMC.,"Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832282/),h,0.25,65214,DB00182,Amphetamine
,22832282,C(max),A pharmacokinetic study found a T(max) of 0.25 h and a C(max) of 1206 ng/ml after 5.6 mg/kg 4-MMC.,"Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832282/),[ng] / [ml],1206,65215,DB00182,Amphetamine
greater,9869367,recovery rates,Solid-phase extraction was used for sample preparation and yielded high recovery rates greater than 95%.,"Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869367/),%,95,65437,DB00182,Amphetamine
,9869367,maximum plasma concentrations,"The maximum plasma concentrations were 235-465 ng/ml (MDE), 67-673 ng/ml (HME) and 7-33 ng/ml (MDA), respectively.","Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869367/),[ng] / [ml],235-465,65438,DB00182,Amphetamine
,9869367,maximum plasma concentrations,"The maximum plasma concentrations were 235-465 ng/ml (MDE), 67-673 ng/ml (HME) and 7-33 ng/ml (MDA), respectively.","Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869367/),[ng] / [ml],67-673,65439,DB00182,Amphetamine
,9869367,maximum plasma concentrations,"The maximum plasma concentrations were 235-465 ng/ml (MDE), 67-673 ng/ml (HME) and 7-33 ng/ml (MDA), respectively.","Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869367/),[ng] / [ml],7-33,65440,DB00182,Amphetamine
,20962030,terminal elimination half-life (t(1/2λz)),"Whereas anti-PCP mAb6B5 terminal elimination half-life (t(1/2λz)) in nonpregnant females was 6.6 ± 1.6 days, the mAb6B5 t(1/2λz) significantly changed to 3.7 ± 0.4 days, then 1.4 ± 0.1 days, then 3.0 ± 0.4 days in the second trimester, third trimester, and postpartum periods, respectively (p < 0.05 for each change).",The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962030/),d,6.6,65669,DB00182,Amphetamine
,20962030,t(1/2λz),"Whereas anti-PCP mAb6B5 terminal elimination half-life (t(1/2λz)) in nonpregnant females was 6.6 ± 1.6 days, the mAb6B5 t(1/2λz) significantly changed to 3.7 ± 0.4 days, then 1.4 ± 0.1 days, then 3.0 ± 0.4 days in the second trimester, third trimester, and postpartum periods, respectively (p < 0.05 for each change).",The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962030/),d,3.7,65670,DB00182,Amphetamine
,20962030,t(1/2λz),"Whereas anti-PCP mAb6B5 terminal elimination half-life (t(1/2λz)) in nonpregnant females was 6.6 ± 1.6 days, the mAb6B5 t(1/2λz) significantly changed to 3.7 ± 0.4 days, then 1.4 ± 0.1 days, then 3.0 ± 0.4 days in the second trimester, third trimester, and postpartum periods, respectively (p < 0.05 for each change).",The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962030/),d,1.4,65671,DB00182,Amphetamine
,20962030,t(1/2λz),"Whereas anti-PCP mAb6B5 terminal elimination half-life (t(1/2λz)) in nonpregnant females was 6.6 ± 1.6 days, the mAb6B5 t(1/2λz) significantly changed to 3.7 ± 0.4 days, then 1.4 ± 0.1 days, then 3.0 ± 0.4 days in the second trimester, third trimester, and postpartum periods, respectively (p < 0.05 for each change).",The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962030/),d,3.0,65672,DB00182,Amphetamine
,19417716,elimination half-life,The elimination half-life of MDMA was considerably shorter in squirrel monkeys than in humans (2-3 versus 6-9 hours).,"Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine (""ecstasy"") disposition and metabolism in squirrel monkeys and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417716/),h,2-3,66347,DB00182,Amphetamine
,19417716,elimination half-life,The elimination half-life of MDMA was considerably shorter in squirrel monkeys than in humans (2-3 versus 6-9 hours).,"Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine (""ecstasy"") disposition and metabolism in squirrel monkeys and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19417716/),h,6-9,66348,DB00182,Amphetamine
,18520604,maximum plasma concentrations (C(max)),"Mean +/- standard deviation maximum plasma concentrations (C(max)) of 162.9 +/- 39.8 and 171.9 +/- 79.5 ng/mL were observed for MDMA and HMMA, respectively, after low-dose MDMA.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],162.9,67224,DB00182,Amphetamine
,18520604,maximum plasma concentrations (C(max)),"Mean +/- standard deviation maximum plasma concentrations (C(max)) of 162.9 +/- 39.8 and 171.9 +/- 79.5 ng/mL were observed for MDMA and HMMA, respectively, after low-dose MDMA.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],171.9,67225,DB00182,Amphetamine
,18520604,Cmax,"After the high dose, mean MDMA Cmax significantly increased to 291.8 +/- 76.5 ng/mL, whereas mean HMMA C(max) was unchanged at 173.5 +/- 66.3 ng/mL.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],291.8,67226,DB00182,Amphetamine
,18520604,C(max),"After the high dose, mean MDMA Cmax significantly increased to 291.8 +/- 76.5 ng/mL, whereas mean HMMA C(max) was unchanged at 173.5 +/- 66.3 ng/mL.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],173.5,67227,DB00182,Amphetamine
,18520604,C(max),Mean MDA C(max) were 8.4 +/- 2.1 (low) and 13.8 +/- 3.8 (high) ng/mL.,"Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],8.4,67228,DB00182,Amphetamine
,18520604,C(max),Mean MDA C(max) were 8.4 +/- 2.1 (low) and 13.8 +/- 3.8 (high) ng/mL.,"Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],13.8,67229,DB00182,Amphetamine
,18520604,Cmax,"HMA Cmax were 3.5 +/- 0.4 and 3.9 +/- 0.9 ng/mL after the low and high doses, respectively.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],3.5,67230,DB00182,Amphetamine
,18520604,Cmax,"HMA Cmax were 3.5 +/- 0.4 and 3.9 +/- 0.9 ng/mL after the low and high doses, respectively.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),[ng] / [ml],3.9,67231,DB00182,Amphetamine
,18520604,half-lives (t1/2),"Mean half-lives (t1/2) of MDMA, MDA, and HMMA were approximately 7 to 8 hours, 10.5 to 12.5 hours, and 11.5 to 13.5 hours, respectively.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),h,7 to 8,67232,DB00182,Amphetamine
,18520604,half-lives (t1/2),"Mean half-lives (t1/2) of MDMA, MDA, and HMMA were approximately 7 to 8 hours, 10.5 to 12.5 hours, and 11.5 to 13.5 hours, respectively.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),h,10.5 to 12.5,67233,DB00182,Amphetamine
,18520604,half-lives (t1/2),"Mean half-lives (t1/2) of MDMA, MDA, and HMMA were approximately 7 to 8 hours, 10.5 to 12.5 hours, and 11.5 to 13.5 hours, respectively.","Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520604/),h,11.5 to 13.5,67234,DB00182,Amphetamine
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,2,67906,DB00182,Amphetamine
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,6.8,67907,DB00182,Amphetamine
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,15,67908,DB00182,Amphetamine
,8321085,Striatal:posterior brain ratios,"Striatal:posterior brain ratios rose from 2 at 25 min to 6.8 at 105 min, to 15 at 4 h and to 58 at 6.4 h.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),,58,67909,DB00182,Amphetamine
,8321085,half-life of washout,[123I]Epidepride was displaced by haloperidol (0.1 and 1 mg/kg) with a half-life of washout of 55 min.,High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),min,55,67910,DB00182,Amphetamine
,8321085,KD,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),pM,46,67911,DB00182,Amphetamine
,8321085,Bmax,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),[pM] / [g·tissue],33,67912,DB00182,Amphetamine
,8321085,KD,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),pM,25,67913,DB00182,Amphetamine
,8321085,Bmax,"In vitro equilibrium binding studies using rat striatum revealed a KD of 46 pM and Bmax of 33 pmol/g tissue at 37 degrees C, while at 25 degrees C the KD was 25 pM and the Bmax 32 pmol/g tissue.",High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),[pM] / [g·tissue],32,67914,DB00182,Amphetamine
,8321085,half-life,In vitro kinetic analysis of association and dissociation curves revealed a half-life for receptor dissociation at 37 degrees C of 15 min and 79-90 min at 25 degrees C.,High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),min,15,67915,DB00182,Amphetamine
,8321085,half-life,In vitro kinetic analysis of association and dissociation curves revealed a half-life for receptor dissociation at 37 degrees C of 15 min and 79-90 min at 25 degrees C.,High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321085/),min,79-90,67916,DB00182,Amphetamine
,30912312,maximal concentrations,"For 12 hours after ingestion, the concentration-time course of 4-FA was similar to that of amphetamine with maximal concentrations appearing in serum after about 2 hours (in median 195 ng/mL after the 100 mg dose, range 155-316 ng/mL).",Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30912312/),[ng] / [ml],195,68840,DB00182,Amphetamine
,30912312,elimination half-life,The elimination half-life was approximately 8-9 hours and shorter than that of amphetamine but it exhibited a marked variation (5.5-16.8 hours).,Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30912312/),h,8-9,68841,DB00182,Amphetamine
,30912312,elimination half-life,The elimination half-life was approximately 8-9 hours and shorter than that of amphetamine but it exhibited a marked variation (5.5-16.8 hours).,Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30912312/),h,5.5-16.8,68842,DB00182,Amphetamine
,1820895,Peak plasma PPA levels,Peak plasma PPA levels were slightly higher for the transdermal patch compared with the tablet formulation (93.6 ng/ml versus 80.10 ng/ml respectively).,In-vivo pharmacokinetic characteristics of a transdermal phenylpropanolamine (PPA) preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820895/),[ng] / [ml],93.6,69362,DB00182,Amphetamine
,1820895,Peak plasma PPA levels,Peak plasma PPA levels were slightly higher for the transdermal patch compared with the tablet formulation (93.6 ng/ml versus 80.10 ng/ml respectively).,In-vivo pharmacokinetic characteristics of a transdermal phenylpropanolamine (PPA) preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820895/),[ng] / [ml],80.10,69363,DB00182,Amphetamine
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.69,69883,DB00182,Amphetamine
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.76,69884,DB00182,Amphetamine
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.98,69885,DB00182,Amphetamine
,8897080,terminal half-lives t1/2,The terminal half-lives t1/2 for selegiline with geometric means of 1.69 h (n = 22) and 1.76 h (n = 21) for treatments A and B and for N-desmethyl-selegiline with geometric means of 1.98 h and 1.96 h for treatments A and B agreed very well.,Bioequivalence evaluation of two preparations containing the highly variable compound selegiline (L-deprenyl). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8897080/),h,1.96,69886,DB00182,Amphetamine
,24884590,pEC50,3-[2-(3-Chloro-5-fluorobenzyl)-1-benzothiophen-7-yl]-N-(2-methoxyethyl)benzamide 7m showed potent activity (pEC50 = 7.53 ± 0.08) and good pharmacokinetic properties.,Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24884590/),,7.53,70033,DB00182,Amphetamine
,27163499,t1/2,"Probenecid prolonged the t1/2 of KUC-7322 from 1.6 to 3.4 hours and decreased the renal clearance and cumulative fraction of KUC-7322 excreted in urine from 18.5 to 4.9 L/h and from 64.7% to 49.7%, respectively.","Investigation of Drug-Drug Interactions Between Ritobegron, a Selective β3 -Adrenoceptor Agonist, With Probenecid in Healthy Men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163499/),h,1,70148,DB00182,Amphetamine
,27163499,renal clearance,"Probenecid prolonged the t1/2 of KUC-7322 from 1.6 to 3.4 hours and decreased the renal clearance and cumulative fraction of KUC-7322 excreted in urine from 18.5 to 4.9 L/h and from 64.7% to 49.7%, respectively.","Investigation of Drug-Drug Interactions Between Ritobegron, a Selective β3 -Adrenoceptor Agonist, With Probenecid in Healthy Men. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27163499/),[l] / [h],18.5,70149,DB00182,Amphetamine
,23545806,"V(max,1)","Measuring the formation of the major metabolite, biphasic Michaelis-Menten kinetic parameters were determined: V(max,1) = 0.046 ± 0.005 (S.E.) nmol/min/mg protein, K(m,1) = 19.0 ± 4.2 μM, V(max,2) = 0.22 ± 0.04 nmol/min/mg protein, and K(m,2) = 1953 ± 761 μM; the low-capacity and high-affinity contribution was assigned to the activity of CYP2D6.",In vitro metabolism and pharmacokinetic studies on methylone. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),[nM] / [mg·min],0.046,72744,DB00182,Amphetamine
,23545806,"K(m,1)","Measuring the formation of the major metabolite, biphasic Michaelis-Menten kinetic parameters were determined: V(max,1) = 0.046 ± 0.005 (S.E.) nmol/min/mg protein, K(m,1) = 19.0 ± 4.2 μM, V(max,2) = 0.22 ± 0.04 nmol/min/mg protein, and K(m,2) = 1953 ± 761 μM; the low-capacity and high-affinity contribution was assigned to the activity of CYP2D6.",In vitro metabolism and pharmacokinetic studies on methylone. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),μM,19.0,72745,DB00182,Amphetamine
,23545806,"V(max,2)","Measuring the formation of the major metabolite, biphasic Michaelis-Menten kinetic parameters were determined: V(max,1) = 0.046 ± 0.005 (S.E.) nmol/min/mg protein, K(m,1) = 19.0 ± 4.2 μM, V(max,2) = 0.22 ± 0.04 nmol/min/mg protein, and K(m,2) = 1953 ± 761 μM; the low-capacity and high-affinity contribution was assigned to the activity of CYP2D6.",In vitro metabolism and pharmacokinetic studies on methylone. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),[nM] / [mg·min],0.22,72746,DB00182,Amphetamine
,23545806,"K(m,2)","Measuring the formation of the major metabolite, biphasic Michaelis-Menten kinetic parameters were determined: V(max,1) = 0.046 ± 0.005 (S.E.) nmol/min/mg protein, K(m,1) = 19.0 ± 4.2 μM, V(max,2) = 0.22 ± 0.04 nmol/min/mg protein, and K(m,2) = 1953 ± 761 μM; the low-capacity and high-affinity contribution was assigned to the activity of CYP2D6.",In vitro metabolism and pharmacokinetic studies on methylone. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),μM,1953,72747,DB00182,Amphetamine
,23545806,K(I),The inactivation parameters were determined to be K(I) = 15.1 ± 3.4 (S.E.) μM and k(inact) = 0.075 ± 0.005 minute(-1).,In vitro metabolism and pharmacokinetic studies on methylone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),μM,15.1,72748,DB00182,Amphetamine
,23545806,k(inact),The inactivation parameters were determined to be K(I) = 15.1 ± 3.4 (S.E.) μM and k(inact) = 0.075 ± 0.005 minute(-1).,In vitro metabolism and pharmacokinetic studies on methylone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),1/[minute],0.075,72749,DB00182,Amphetamine
,12586207,K(d),Our studies examined pharmacokinetic mechanisms involved in high-affinity (K(d) approximately 11 nM) monoclonal antibody-based antagonism of (+)-methamphetamine-induced locomotor effects.,Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586207/),nM,11,75019,DB00182,Amphetamine
,12507968,c(max),"After the first oral dose, initial plasma METH detection was within 0.25-2 h; c(max) was 14.5-33.8 micro g/L (10 mg) and 26.2-44.3 micro g/L (20 mg) within 2-12 h.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),[μg] / [l],14.5-33.8,76508,DB00182,Amphetamine
,12507968,c(max),"After the first oral dose, initial plasma METH detection was within 0.25-2 h; c(max) was 14.5-33.8 micro g/L (10 mg) and 26.2-44.3 micro g/L (20 mg) within 2-12 h.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),[μg] / [l],26.2-44.3,76509,DB00182,Amphetamine
,12507968,c(max),"In oral fluid, METH was detected as early as 0.08-2 h; c(max) was 24.7-312.2 micro g/L (10 mg) and 75.3-321.7 micro g/L (20 mg) and occurred at 2-12 h.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),[μg] / [l],24.7-312.2,76510,DB00182,Amphetamine
,12507968,c(max),"In oral fluid, METH was detected as early as 0.08-2 h; c(max) was 24.7-312.2 micro g/L (10 mg) and 75.3-321.7 micro g/L (20 mg) and occurred at 2-12 h.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),[μg] / [l],75.3-321.7,76511,DB00182,Amphetamine
,12507968,oral fluid-plasma METH,The median oral fluid-plasma METH concentration ratio was 2.0 across 24 h and was highly variable.,Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),,2.0,76512,DB00182,Amphetamine
,12507968,concentration ratio,The median oral fluid-plasma METH concentration ratio was 2.0 across 24 h and was highly variable.,Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),,2.0,76513,DB00182,Amphetamine
,12507968,areas under the curve,"Mean (SD) areas under the curve for AMP were 21% +/- 25% and 24% +/- 11% of those observed for METH in plasma and oral fluid, respectively.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),,21,76514,DB00182,Amphetamine
,12507968,areas under the curve,"Mean (SD) areas under the curve for AMP were 21% +/- 25% and 24% +/- 11% of those observed for METH in plasma and oral fluid, respectively.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),%,24,76515,DB00182,Amphetamine
,12507968,detection window,"After a single low or high dose, plasma METH was >2.5 micro g/L for up to 24 h in 9 of 12 individuals (mean, 7.3 +/- 5.5 micro g/L at 24 h); in oral fluid the detection window was at least 24 h (mean, 18.8 +/- 18.0 micro g/L at 24 h).",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),[μg] / [l],18.8,76516,DB00182,Amphetamine
,19679675,maximum MDMA concentrations (C(max)),"After 2 mg/kg, maximum MDMA concentrations (C(max)) were approximately 200 ng/ml for intraperitoneal and subcutaneous routes, but less for the oral route.","Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679675/),[ng] / [ml],200,79089,DB00182,Amphetamine
<,19679675,plasma half-lives,"MDMA plasma half-lives were <1 h for low-dose groups, whereas HMMA and MDA half-lives were >2 h.","Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679675/),h,1,79090,DB00182,Amphetamine
>,19679675,half-lives,"MDMA plasma half-lives were <1 h for low-dose groups, whereas HMMA and MDA half-lives were >2 h.","Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19679675/),h,2,79091,DB00182,Amphetamine
,23603357,α,The plasma concentrations after i.v. administration were described by a two-compartment model with distribution and terminal elimination phases of α=1.95 h(-1) and β=0.72 h(-1).,"An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as ""bath salts"". ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23603357/),1/[h],1.95,81812,DB00182,Amphetamine
,23603357,β,The plasma concentrations after i.v. administration were described by a two-compartment model with distribution and terminal elimination phases of α=1.95 h(-1) and β=0.72 h(-1).,"An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as ""bath salts"". ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23603357/),1/[h],0.72,81813,DB00182,Amphetamine
,23603357,Absolute bioavailability,Absolute bioavailability was about 80% and the percentage of methylone protein binding was of 30%.,"An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as ""bath salts"". ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23603357/),%,80,81814,DB00182,Amphetamine
,23603357,percentage of,Absolute bioavailability was about 80% and the percentage of methylone protein binding was of 30%.,"An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as ""bath salts"". ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23603357/),%,30,81815,DB00182,Amphetamine
,9797797,Peak serum concentrations,Peak serum concentrations of selegiline were reached rapidly and ranged from 1 to 32 nmol/L.,CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[nM] / [l],1 to 32,84693,DB00182,Amphetamine
,9797797,50% inhibitory concentration,"The inhibitory potency of selegiline, desmethylselegiline, and l-methamphetamine toward dextromethorphan O-demethylase was very low (50% inhibitory concentration values from 160 to 580 mumol/L).",CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[μM] / [l],160 to 580,84694,DB00182,Amphetamine
,14871155,distribution volume,"Their oral bioavailability is good, with a high distribution volume (4 L/kg) and low binding to plasma proteins (less than 20%).",Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14871155/),[l] / [kg],4,85473,DB00182,Amphetamine
,14871155,elimination half-life,The elimination half-life is 6-12 hours.,Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14871155/),h,6-12,85474,DB00182,Amphetamine
,14871155,pKa,"Amfetamine and related compounds are weak bases, with a pKa around 9.9, and a relatively low molecular weight.",Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14871155/),,9.9,85475,DB00182,Amphetamine
,27474358,limits of detection,"These conditions allowed for limits of detection of 1ng/mL for MDPV, and 5 ng/mL for both mephedrone and methylone.",Quantification of Synthetic Cathinones in Rat Brain Using HILIC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474358/),[ng] / [ml],1,87074,DB00182,Amphetamine
,27474358,limits of detection,"These conditions allowed for limits of detection of 1ng/mL for MDPV, and 5 ng/mL for both mephedrone and methylone.",Quantification of Synthetic Cathinones in Rat Brain Using HILIC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474358/),[ng] / [ml],5,87075,DB00182,Amphetamine
,18192498,K(d),"With medical treatment as a goal, a novel single-chain variable fragment (scFv) against METH was engineered from anti-METH monoclonal antibody mAb6H4 (IgG, kappa light chain, K(d) = 11 nM) and found to have similar ligand affinity (K(d) = 10 nM) and specificity as mAb6H4.",Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192498/),nM,11,87800,DB00182,Amphetamine
,18192498,K(d),"With medical treatment as a goal, a novel single-chain variable fragment (scFv) against METH was engineered from anti-METH monoclonal antibody mAb6H4 (IgG, kappa light chain, K(d) = 11 nM) and found to have similar ligand affinity (K(d) = 10 nM) and specificity as mAb6H4.",Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192498/),nM,10,87801,DB00182,Amphetamine
,18192498,apparent t(1/2lambdaz),The scFv6H4 monomer was quickly cleared or converted to multivalent forms with an apparent t(1/2lambdaz) of 5.8 min.,Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192498/),min,5.8,87802,DB00182,Amphetamine
,18192498,t(1/2lambdaz),"In contrast, the larger scFv6H4 multivalent forms (dimers, trimers, etc.) showed a much longer t(1/2lambdaz) (228 min), and the significantly increased METH serum molar concentrations correlated directly with scFv6H4 serum molar concentrations.",Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192498/),min,228,87803,DB00182,Amphetamine
,11559034,C(max),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [l],154.5,88271,DB00182,Amphetamine
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [h·l],1990.9,88272,DB00182,Amphetamine
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [l],181.6,88273,DB00182,Amphetamine
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [h·l],1465.9,88274,DB00182,Amphetamine
,17625500,peak plasma METH concentrations,"METH doses were escalated over 33 weeks, with final dosages resulting in estimated peak plasma METH concentrations of 1-3 microM, a range measured in human abusers.",Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17625500/),μM,1-3,88339,DB00182,Amphetamine
,30614204,initial detection time,"After oral administration, each analyte could be detected in OF specimens from all volunteers with an initial detection time of 0.50 hours.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,0.50,89117,DB00182,Amphetamine
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],50.93-992.67,89118,DB00182,Amphetamine
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],29.78-653.64,89119,DB00182,Amphetamine
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],8.22-150.15,89120,DB00182,Amphetamine
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],4.34-16.25,89121,DB00182,Amphetamine
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,5-24,89122,DB00182,Amphetamine
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,52-96,89123,DB00182,Amphetamine
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,31-96,89124,DB00182,Amphetamine
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,13-31,89125,DB00182,Amphetamine
,28910145,Tmax,IR formulations typically provide a Tmax from 2 to 3 hours.,The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28910145/),h,2 to 3,89339,DB00182,Amphetamine
,28910145,plasma T1/2,"In replicated studies, children exhibit a shorter plasma T1/2 (∼7 hours) relative to adults (∼10 to 12 hours).",The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28910145/),h,∼7,89340,DB00182,Amphetamine
,28910145,plasma T1/2,"In replicated studies, children exhibit a shorter plasma T1/2 (∼7 hours) relative to adults (∼10 to 12 hours).",The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28910145/),h,12,89341,DB00182,Amphetamine
,31295008,AUC0-inf,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[h·ng] / [ml],315.2,89450,DB00182,Amphetamine
,31295008,AUC0-inf,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[h·ng] / [ml],104.4,89451,DB00182,Amphetamine
,31295008,AUC0-T,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[h·ng] / [ml],296.0,89452,DB00182,Amphetamine
,31295008,AUC0-T,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[h·ng] / [ml],96.8,89453,DB00182,Amphetamine
,31295008,t1/2,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),h,8.0,89454,DB00182,Amphetamine
,31295008,t1/2,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),h,9.2,89455,DB00182,Amphetamine
,31295008,Cmax,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[ng] / [ml],23.0,89456,DB00182,Amphetamine
,31295008,Cmax,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[ng] / [ml],7.0,89457,DB00182,Amphetamine
,31295008,Tmax,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),h,3.9,89458,DB00182,Amphetamine
,31295008,Tmax,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),h,4.0,89459,DB00182,Amphetamine
,31295008,CL/F,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[ml] / [h],6996.3,89460,DB00182,Amphetamine
,31295008,CL/F,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),[ml] / [h],6837.1,89461,DB00182,Amphetamine
,31295008,Vz/F,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),ml,"75,874.5",89462,DB00182,Amphetamine
,31295008,Vz/F,"For d- and l-AMP, mean AUC0-inf was 315.2 and 104.4 h·ng/mL, AUC0-T was 296.0 and 96.8 h·ng/mL, t1/2 was 8.0 and 9.2 hours, Cmax was 23.0 and 7.0 ng/mL, Tmax was 3.9 and 4.0 hours, CL/F was 6996.3 and 6837.1 mL/h, and Vz/F was 75,874.5 and 84,140.0 mL, respectively.","An Open-Label, Multicenter, Single-Dose Pharmacokinetic Study of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Preschool-Aged Children. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31295008/),ml,"84,140.0",89463,DB00182,Amphetamine
,9248947,hair concentrations,"The hair concentrations of FNT and AP were 52 +/- 1.4 and 4.9 +/- 0.6 ng/mg, whereas those of plasma AUCs were 55.9 +/- 23.1 and 22.3 +/- 4.9 micrograms.min/mL, respectively.",Hair analysis for drugs of abuse. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248947/),[ng] / [mg],52,90368,DB00182,Amphetamine
,9248947,hair concentrations,"The hair concentrations of FNT and AP were 52 +/- 1.4 and 4.9 +/- 0.6 ng/mg, whereas those of plasma AUCs were 55.9 +/- 23.1 and 22.3 +/- 4.9 micrograms.min/mL, respectively.",Hair analysis for drugs of abuse. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248947/),[ng] / [mg],4.9,90369,DB00182,Amphetamine
,9248947,plasma AUCs,"The hair concentrations of FNT and AP were 52 +/- 1.4 and 4.9 +/- 0.6 ng/mg, whereas those of plasma AUCs were 55.9 +/- 23.1 and 22.3 +/- 4.9 micrograms.min/mL, respectively.",Hair analysis for drugs of abuse. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248947/),[min·μg] / [ml],55.9,90370,DB00182,Amphetamine
,9248947,plasma AUCs,"The hair concentrations of FNT and AP were 52 +/- 1.4 and 4.9 +/- 0.6 ng/mg, whereas those of plasma AUCs were 55.9 +/- 23.1 and 22.3 +/- 4.9 micrograms.min/mL, respectively.",Hair analysis for drugs of abuse. Disposition of fenethylline and its metabolite into hair and discrimination between fenethylline use and amphetamine use by hair analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9248947/),[min·μg] / [ml],22.3,90371,DB00182,Amphetamine
,15570192,Maximum excretion rates,Maximum excretion rates ranged from 403 to 4919 microg/h for methamphetamine and 59 to 735 microg/h for amphetamine with no relationship between dose and excretion rate.,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),[μg] / [h],403 to 4919,92827,DB00182,Amphetamine
,15570192,Maximum excretion rates,Maximum excretion rates ranged from 403 to 4919 microg/h for methamphetamine and 59 to 735 microg/h for amphetamine with no relationship between dose and excretion rate.,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),[μg] / [h],59 to 735,92828,DB00182,Amphetamine
,15570192,molar percentage of dose,The mean molar percentage of dose in the urine as total methamphetamine and amphetamine were 57.5 +/- 21.7% (low dose) and 40.9 +/- 8.5% (high dose).,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),%,57.5,92829,DB00182,Amphetamine
,15570192,molar percentage of dose,The mean molar percentage of dose in the urine as total methamphetamine and amphetamine were 57.5 +/- 21.7% (low dose) and 40.9 +/- 8.5% (high dose).,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),%,40.9,92830,DB00182,Amphetamine
,15570192,urinary terminal elimination half-lives,Mean urinary terminal elimination half-lives across doses were 23.6 +/- 6.6 hours for methamphetamine and 20.7 +/- 7.3 hours for amphetamine.,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),h,23.6,92831,DB00182,Amphetamine
,15570192,urinary terminal elimination half-lives,Mean urinary terminal elimination half-lives across doses were 23.6 +/- 6.6 hours for methamphetamine and 20.7 +/- 7.3 hours for amphetamine.,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),h,20.7,92832,DB00182,Amphetamine
,15570192,renal clearance,Methamphetamine renal clearance across doses was 175 +/- 102 mL/min.,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),[ml] / [min],175,92833,DB00182,Amphetamine
,21151866,clearance,"Methamphetamine's clearance was fastest in heart and lungs (7-16 minutes), slowest in brain, liver and stomach (>75 minutes), and intermediate in kidneys, spleen and pancreas (22-50 minutes).",Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21151866/),min,7-16,97494,DB00182,Amphetamine
>,21151866,clearance,"Methamphetamine's clearance was fastest in heart and lungs (7-16 minutes), slowest in brain, liver and stomach (>75 minutes), and intermediate in kidneys, spleen and pancreas (22-50 minutes).",Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21151866/),min,75,97495,DB00182,Amphetamine
,21151866,clearance,"Methamphetamine's clearance was fastest in heart and lungs (7-16 minutes), slowest in brain, liver and stomach (>75 minutes), and intermediate in kidneys, spleen and pancreas (22-50 minutes).",Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21151866/),min,22-50,97496,DB00182,Amphetamine
,29971461,Cmax,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l],16.4,104026,DB00182,Amphetamine
,29971461,Cmax,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l],62.2,104027,DB00182,Amphetamine
,29971461,AUC0 → ∞,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l·min],708,104028,DB00182,Amphetamine
,29971461,AUC0 → ∞,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l·min],3316,104029,DB00182,Amphetamine
,29971461,V/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg],582.6,104030,DB00182,Amphetamine
,29971461,V/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg],115.9,104031,DB00182,Amphetamine
,29971461,Cl/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg·min],4.6,104032,DB00182,Amphetamine
,29971461,Cl/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg·min],1.2,104033,DB00182,Amphetamine
,29971461,EC50,"The sigmoidal Emax model fitted the observed data well; MDPV being markedly more potent than 4-MMC (EC50, 0.043 versus 0.7 μmol/L).","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μM] / [l],0.043,104034,DB00182,Amphetamine
,29971461,EC50,"The sigmoidal Emax model fitted the observed data well; MDPV being markedly more potent than 4-MMC (EC50, 0.043 versus 0.7 μmol/L).","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μM] / [l],0.7,104035,DB00182,Amphetamine
,23649883,α,"Mephedrone plasma concentrations after i.v. administration fit a two-compartment model (α = 10.23 h(-1), β = 1.86 h(-1)).",Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),1/[h],10.23,106059,DB00182,Amphetamine
,23649883,β,"Mephedrone plasma concentrations after i.v. administration fit a two-compartment model (α = 10.23 h(-1), β = 1.86 h(-1)).",Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),1/[h],1.86,106060,DB00182,Amphetamine
,23649883,absolute bioavailability,The absolute bioavailability of mephedrone was about 10% and the percentage of mephedrone protein binding was 21.59 ± 3.67%.,Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),%,10,106061,DB00182,Amphetamine
,23649883,percentage of,The absolute bioavailability of mephedrone was about 10% and the percentage of mephedrone protein binding was 21.59 ± 3.67%.,Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),%,21.59,106062,DB00182,Amphetamine
,23649883,protein binding,The absolute bioavailability of mephedrone was about 10% and the percentage of mephedrone protein binding was 21.59 ± 3.67%.,Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),%,21.59,106063,DB00182,Amphetamine
,25310201,maximum plasma concentration,"With ascending LDX dose, the mean (SD) maximum plasma concentration for LDX-derived d-amphetamine ranged from 51.68 (10.28) to 266.27 (56.55) ng/mL.","Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25310201/),[ng] / [ml],51.68,106953,DB00182,Amphetamine
,25310201,maximum plasma concentration,"With ascending LDX dose, the mean (SD) maximum plasma concentration for LDX-derived d-amphetamine ranged from 51.68 (10.28) to 266.27 (56.55) ng/mL.","Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25310201/),[ng] / [ml],266.27,106954,DB00182,Amphetamine
,25310201,area under the plasma concentration-time curve for 24 hours,The area under the plasma concentration-time curve for 24 hours ranged from 801.8 (170.2) to 4397.9 (1085.9) ng[BULLET OPERATOR]h/mL.,"Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25310201/),ng,801.8,106955,DB00182,Amphetamine
,25310201,area under the plasma concentration-time curve for 24 hours,The area under the plasma concentration-time curve for 24 hours ranged from 801.8 (170.2) to 4397.9 (1085.9) ng[BULLET OPERATOR]h/mL.,"Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25310201/),ng,4397.9,106956,DB00182,Amphetamine
,17015058,elimination half-lives,The elimination half-lives were longer for l-methamphetamine (13.3-15.0 hours) than for d-methamphetamine (10.2-10.7 hours) (P < .0001).,Human pharmacology of the methamphetamine stereoisomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),h,13.3-15.0,107796,DB00182,Amphetamine
,17015058,elimination half-lives,The elimination half-lives were longer for l-methamphetamine (13.3-15.0 hours) than for d-methamphetamine (10.2-10.7 hours) (P < .0001).,Human pharmacology of the methamphetamine stereoisomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),h,10.2-10.7,107797,DB00182,Amphetamine
,17015058,peak heart rate changes,"The peak heart rate changes after racemic methamphetamine and 0.5 mg/kg d- and l-methamphetamine were similar (18.7 +/- 23.4 beats/min, 13.5 +/- 18.5 beats/min, and 10.7 +/- 10.2 beats/min, respectively), but racemic methamphetamine and 0.5 mg/kg d-methamphetamine increased systolic blood pressure more than 0.5 mg/kg l-methamphetamine (33.4 +/- 17.8 beats/min and 34.5 +/- 18.9 beats/min, respectively, versus 19.5 +/- 11.3 beats/min; P < .01).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),[beats] / [min],18.7,107798,DB00182,Amphetamine
,17015058,peak heart rate changes,"The peak heart rate changes after racemic methamphetamine and 0.5 mg/kg d- and l-methamphetamine were similar (18.7 +/- 23.4 beats/min, 13.5 +/- 18.5 beats/min, and 10.7 +/- 10.2 beats/min, respectively), but racemic methamphetamine and 0.5 mg/kg d-methamphetamine increased systolic blood pressure more than 0.5 mg/kg l-methamphetamine (33.4 +/- 17.8 beats/min and 34.5 +/- 18.9 beats/min, respectively, versus 19.5 +/- 11.3 beats/min; P < .01).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),[beats] / [min],13.5,107799,DB00182,Amphetamine
,17015058,peak heart rate changes,"The peak heart rate changes after racemic methamphetamine and 0.5 mg/kg d- and l-methamphetamine were similar (18.7 +/- 23.4 beats/min, 13.5 +/- 18.5 beats/min, and 10.7 +/- 10.2 beats/min, respectively), but racemic methamphetamine and 0.5 mg/kg d-methamphetamine increased systolic blood pressure more than 0.5 mg/kg l-methamphetamine (33.4 +/- 17.8 beats/min and 34.5 +/- 18.9 beats/min, respectively, versus 19.5 +/- 11.3 beats/min; P < .01).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),[beats] / [min],10.7,107800,DB00182,Amphetamine
,17015058,peak heart rate changes,"The peak heart rate changes after racemic methamphetamine and 0.5 mg/kg d- and l-methamphetamine were similar (18.7 +/- 23.4 beats/min, 13.5 +/- 18.5 beats/min, and 10.7 +/- 10.2 beats/min, respectively), but racemic methamphetamine and 0.5 mg/kg d-methamphetamine increased systolic blood pressure more than 0.5 mg/kg l-methamphetamine (33.4 +/- 17.8 beats/min and 34.5 +/- 18.9 beats/min, respectively, versus 19.5 +/- 11.3 beats/min; P < .01).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),[beats] / [min],19,107801,DB00182,Amphetamine
,17015058,peak intoxication,"l-Methamphetamine, 0.5 mg/kg, was psychoactive, producing peak intoxication (46.0 +/- 35.3 versus 30.3 +/- 24.9) and drug liking (47.7 +/- 35.1 versus 28.6 +/- 24.8) ratings similar to 0.5 mg/kg d-methamphetamine, but the effects of l-methamphetamine dissipated more quickly (approximately 3 hours versus 6 hours).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),,46,107802,DB00182,Amphetamine
,17015058,peak intoxication,"l-Methamphetamine, 0.5 mg/kg, was psychoactive, producing peak intoxication (46.0 +/- 35.3 versus 30.3 +/- 24.9) and drug liking (47.7 +/- 35.1 versus 28.6 +/- 24.8) ratings similar to 0.5 mg/kg d-methamphetamine, but the effects of l-methamphetamine dissipated more quickly (approximately 3 hours versus 6 hours).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),,30.3,107803,DB00182,Amphetamine
,17015058,drug,"l-Methamphetamine, 0.5 mg/kg, was psychoactive, producing peak intoxication (46.0 +/- 35.3 versus 30.3 +/- 24.9) and drug liking (47.7 +/- 35.1 versus 28.6 +/- 24.8) ratings similar to 0.5 mg/kg d-methamphetamine, but the effects of l-methamphetamine dissipated more quickly (approximately 3 hours versus 6 hours).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),,47.7,107804,DB00182,Amphetamine
,17015058,drug,"l-Methamphetamine, 0.5 mg/kg, was psychoactive, producing peak intoxication (46.0 +/- 35.3 versus 30.3 +/- 24.9) and drug liking (47.7 +/- 35.1 versus 28.6 +/- 24.8) ratings similar to 0.5 mg/kg d-methamphetamine, but the effects of l-methamphetamine dissipated more quickly (approximately 3 hours versus 6 hours).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),,28.6,107805,DB00182,Amphetamine
,22588199,t(max),A log brain/plasma concentration ratio at a t(max) of 1.48 suggests that SYA013 readily crosses the blood brain barrier (BBB).,"Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22588199/),,1.48,109056,DB00182,Amphetamine
,15808002,detection time,"In the case of doping analysis, the reliable detection time for mesocarb (long-life dihydroxymesocarb metabolites of mesocarb) is approximately 10-11 days after the administration of the drug, which is a significant increase over the existing data.",Validation of liquid chromatography-electrospray ionization ion trap mass spectrometry method for the determination of mesocarb in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15808002/),d,10-11,113729,DB00182,Amphetamine
,15808002,recoveries,"The mean recoveries from plasma are 49.2% and 57.4% for mesocarb concentrations of 33.0 and 66.0 ng/mL, respectively, whereas the recoveries from human urine are 76.9% and 81.4% for concentrations of 1 and 2 ng/mL, respectively.",Validation of liquid chromatography-electrospray ionization ion trap mass spectrometry method for the determination of mesocarb in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15808002/),%,49.2,113730,DB00182,Amphetamine
,15808002,recoveries,"The mean recoveries from plasma are 49.2% and 57.4% for mesocarb concentrations of 33.0 and 66.0 ng/mL, respectively, whereas the recoveries from human urine are 76.9% and 81.4% for concentrations of 1 and 2 ng/mL, respectively.",Validation of liquid chromatography-electrospray ionization ion trap mass spectrometry method for the determination of mesocarb in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15808002/),%,57.4,113731,DB00182,Amphetamine
,15808002,recoveries,"The mean recoveries from plasma are 49.2% and 57.4% for mesocarb concentrations of 33.0 and 66.0 ng/mL, respectively, whereas the recoveries from human urine are 76.9% and 81.4% for concentrations of 1 and 2 ng/mL, respectively.",Validation of liquid chromatography-electrospray ionization ion trap mass spectrometry method for the determination of mesocarb in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15808002/),%,76.9,113732,DB00182,Amphetamine
,15808002,recoveries,"The mean recoveries from plasma are 49.2% and 57.4% for mesocarb concentrations of 33.0 and 66.0 ng/mL, respectively, whereas the recoveries from human urine are 76.9% and 81.4% for concentrations of 1 and 2 ng/mL, respectively.",Validation of liquid chromatography-electrospray ionization ion trap mass spectrometry method for the determination of mesocarb in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15808002/),%,81.4,113733,DB00182,Amphetamine
,14570763,KD,These studies examined the effects of a high-affinity anti-(+)-methamphetamine monoclonal antibody (mAb; KD = 11 nM) on (+)-methamphetamine [(+)-METH] and (+)-amphetamine [(+)-AMP] serum and tissue disposition and serum protein binding following i.v. (+)-METH administration.,Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570763/),nM,11,114263,DB00182,Amphetamine
,7995016,half-life of recovery,"In rat brain the half-life of recovery in the brain is approximately 8 to 12 days; in rat liver it is shorter, 1 to 3 days.",Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995016/),d,8 to 12,114602,DB00182,Amphetamine
,7995016,half-life of recovery,"In rat brain the half-life of recovery in the brain is approximately 8 to 12 days; in rat liver it is shorter, 1 to 3 days.",Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995016/),d,1 to 3,114603,DB00182,Amphetamine
,31642004,C0,The primary PK parameters determined by WinNonlin were a C0 (ng/mL) of 1412.09 ± 196.12 and a plasma half-life of 2.27 ± 0.67 h.,The pharmacokinetics of 3-fluoroamphetamine following delivery using clinically relevant routes of administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31642004/),[ng] / [ml],1412.09,114662,DB00182,Amphetamine
,31642004,plasma half-life,The primary PK parameters determined by WinNonlin were a C0 (ng/mL) of 1412.09 ± 196.12 and a plasma half-life of 2.27 ± 0.67 h.,The pharmacokinetics of 3-fluoroamphetamine following delivery using clinically relevant routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31642004/),h,2.27,114663,DB00182,Amphetamine
,26861609,t1/2,"Pharmacokinetic studies showed elimination half-life of l-DOPA in the plasma after DopAmide treatment of t1/2 = 4.1 h, significantly longer than t1/2 = 2.9 h after treatment with l-DOPA, consistent with the 6-OHDA results.","DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861609/),h,4.1,117581,DB00182,Amphetamine
,26861609,t1/2,"Pharmacokinetic studies showed elimination half-life of l-DOPA in the plasma after DopAmide treatment of t1/2 = 4.1 h, significantly longer than t1/2 = 2.9 h after treatment with l-DOPA, consistent with the 6-OHDA results.","DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26861609/),h,2.9,117582,DB00182,Amphetamine
,27658484,Tmax,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,15-45,119370,DB00182,Amphetamine
,27658484,t1/2,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,60-90,119371,DB00182,Amphetamine
,27658484,Tmax,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,60-120,119372,DB00182,Amphetamine
,27658484,t1/2,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,120-180,119373,DB00182,Amphetamine
,17629428,peak plasma level,"After per oral application, DOB peak plasma level of 320 ng/mL was reached after one-hour post dosing as well as 2M5H4BA peak concentration of 203 ng/mL.","Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17629428/),[ng] / [ml],320,122321,DB00182,Amphetamine
,17629428,peak concentration,"After per oral application, DOB peak plasma level of 320 ng/mL was reached after one-hour post dosing as well as 2M5H4BA peak concentration of 203 ng/mL.","Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17629428/),[ng] / [ml],203,122322,DB00182,Amphetamine
,17629428,maximum plasma concentration,"DOB maximum plasma concentration of 1143 ng/mL was reached after one-hour post application, whereas its metabolite peak level after 8 h was 213 ng/mL.","Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17629428/),[ng] / [ml],1143,122323,DB00182,Amphetamine
,17629428,peak level,"DOB maximum plasma concentration of 1143 ng/mL was reached after one-hour post application, whereas its metabolite peak level after 8 h was 213 ng/mL.","Distribution profile of 2,5-dimethoxy-4-bromoamphetamine (DOB) in rats after oral and subcutaneous doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17629428/),[ng] / [ml],213,122324,DB00182,Amphetamine
>,11862224,first-pass extraction,"The transdermal administration of SEL bypasses the first-pass metabolism, that is significant after oral administration (first-pass extraction >90%).",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),%,90,125181,DB00182,Amphetamine
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],1.19,125182,DB00182,Amphetamine
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],23.22,125183,DB00182,Amphetamine
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],4.78,125184,DB00182,Amphetamine
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],14.08,125185,DB00182,Amphetamine
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],2.10,125186,DB00182,Amphetamine
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],0.85,125187,DB00182,Amphetamine
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],1.06,125188,DB00182,Amphetamine
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],2.71,125189,DB00182,Amphetamine
,32986113,Tmax,"Compared to other psychostimulants, mephedrone showed rapid absorption (mean Tmax of 52.5 ± 20.7 min in plasma and 55.0 ± 18.2 min in whole blood) and elimination (mean t1/2 of 1.98 ± 0.30 h in plasma and 2.12 ± 0.33 h in whole blood).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),min,52.5,125557,DB00182,Amphetamine
,32986113,Tmax,"Compared to other psychostimulants, mephedrone showed rapid absorption (mean Tmax of 52.5 ± 20.7 min in plasma and 55.0 ± 18.2 min in whole blood) and elimination (mean t1/2 of 1.98 ± 0.30 h in plasma and 2.12 ± 0.33 h in whole blood).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),min,55.0,125558,DB00182,Amphetamine
,32986113,t1/2,"Compared to other psychostimulants, mephedrone showed rapid absorption (mean Tmax of 52.5 ± 20.7 min in plasma and 55.0 ± 18.2 min in whole blood) and elimination (mean t1/2 of 1.98 ± 0.30 h in plasma and 2.12 ± 0.33 h in whole blood).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),h,1.98,125559,DB00182,Amphetamine
,32986113,t1/2,"Compared to other psychostimulants, mephedrone showed rapid absorption (mean Tmax of 52.5 ± 20.7 min in plasma and 55.0 ± 18.2 min in whole blood) and elimination (mean t1/2 of 1.98 ± 0.30 h in plasma and 2.12 ± 0.33 h in whole blood).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),h,2.12,125560,DB00182,Amphetamine
,32986113,whole blood to plasma distribution ratios,"In addition, statistical analysis showed that median whole blood to plasma distribution ratios, reported here for the first time, were statistically different from 1 (unity) for mephedrone (median: 1.11), DHM (median: 1.30) and NOR (median: 0.765).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),,1,125561,DB00182,Amphetamine
,32986113,whole blood to plasma distribution ratios,"In addition, statistical analysis showed that median whole blood to plasma distribution ratios, reported here for the first time, were statistically different from 1 (unity) for mephedrone (median: 1.11), DHM (median: 1.30) and NOR (median: 0.765).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),,0,125562,DB00182,Amphetamine
,6628439,half-life,When the mouse was pretreated with a MAO inhibitor (pargyline hydrochloride 100 mg/kg IP) the radioactivity was rapidly excreted from the brain with a half-life of about 45 min.,A new metabolically trapped agent by brain monoamine oxidase: N-methyl labeled (14C) N-methylphenylethylamine (14C-MPEA). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628439/),min,45,125694,DB00182,Amphetamine
,11568088,Salivary concentrations,Salivary concentrations of MDMA were 1728.9-6510.6 microg/L and peaked at 1.5 h after drug intake.,"Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568088/),[μg] / [l],1728.9-6510.6,127330,DB00182,Amphetamine
,11568088,saliva-to-plasma ratio,"The saliva-to-plasma ratio was 32.3-1.2, with a peak of 18.1 at 1.5 h after drug administration.","Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568088/),,32.3-1.2,127331,DB00182,Amphetamine
,20535053,total MPH excreted,Mean total MPH excreted was 0.02 mg (about 0.08% of the administered dose).,Usefulness of sweat testing for the detection of methylphenidate after fast- and extended-release drug administration: a pilot study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20535053/),mg,0.02,128946,DB00182,Amphetamine
,20535053,total MPH excreted,Mean total MPH excreted was 0.04 mg (about 0.18% of the administered dose).,Usefulness of sweat testing for the detection of methylphenidate after fast- and extended-release drug administration: a pilot study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20535053/),mg,0.04,128947,DB00182,Amphetamine
,9638577,recoveries,The recoveries of TA-2005-glucuronide spiked to plasma samples were 95.5-120% (inter-assay) and 96.0-123.3% (intra-assay).,Enzyme-linked immunosorbent assay for TA-2005-glucuronide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638577/),%,95.5-120,130310,DB00182,Amphetamine
,9638577,recoveries,The recoveries of TA-2005-glucuronide spiked to plasma samples were 95.5-120% (inter-assay) and 96.0-123.3% (intra-assay).,Enzyme-linked immunosorbent assay for TA-2005-glucuronide in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638577/),%,96.0-123.3,130311,DB00182,Amphetamine
,31094571,zeta potential,"Results: Risperidone nanoparticles (RP12) were produced with an average size of 86 nm, polydispersity index of 0.287, zeta potential of +36.6 mV, mucoadhesion of 68.9% and entrapment efficiency of 77.96%.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),mv,+,131619,DB00182,Amphetamine
,31094571,zeta potential,"Results: Risperidone nanoparticles (RP12) were produced with an average size of 86 nm, polydispersity index of 0.287, zeta potential of +36.6 mV, mucoadhesion of 68.9% and entrapment efficiency of 77.96%.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),mv,36.6,131620,DB00182,Amphetamine
,31094571,mucoadhesion,"Results: Risperidone nanoparticles (RP12) were produced with an average size of 86 nm, polydispersity index of 0.287, zeta potential of +36.6 mV, mucoadhesion of 68.9% and entrapment efficiency of 77.96%.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),%,68.9,131621,DB00182,Amphetamine
,31094571,entrapment efficiency,"Results: Risperidone nanoparticles (RP12) were produced with an average size of 86 nm, polydispersity index of 0.287, zeta potential of +36.6 mV, mucoadhesion of 68.9% and entrapment efficiency of 77.96%.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),%,77.96,131622,DB00182,Amphetamine
,31094571,Maximum concentration,"Maximum concentration of RS in plasma was 1240 ng/ml at 4 h for RP12, and 403.8 ng/ml at 2 h for RS sample.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),[ng] / [ml],1240,131623,DB00182,Amphetamine
,31094571,Maximum concentration,"Maximum concentration of RS in plasma was 1240 ng/ml at 4 h for RP12, and 403.8 ng/ml at 2 h for RS sample.",Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094571/),[ng] / [ml],403.8,131624,DB00182,Amphetamine
,20006596,K(i),SCH 486757 selectively binds human NOP receptor (K(i)=4.6+/-0.61nM) over classical opioid receptors.,Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20006596/),nM,4.6,132212,DB00182,Amphetamine
,12798189,flow rate,"The chromatographic conditions consisted of an ODS column and mobile phase composition of acetonitrile and water (65:35, v/v) with flow rate set at 1.0 ml/min.",Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12798189/),[ml] / [min],1.0,134586,DB00182,Amphetamine
less,12798189,detection limits,The obtained detection limits were less than 23 fmol on column (for the three compounds) in both brain and blood microdialysates at a signal-to-noise ratio of 3 (S/N=3).,Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12798189/),fmol,23,134587,DB00182,Amphetamine
,12798189,signal-to-noise ratio,The obtained detection limits were less than 23 fmol on column (for the three compounds) in both brain and blood microdialysates at a signal-to-noise ratio of 3 (S/N=3).,Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12798189/),,3,134588,DB00182,Amphetamine
,12798189,S/N,The obtained detection limits were less than 23 fmol on column (for the three compounds) in both brain and blood microdialysates at a signal-to-noise ratio of 3 (S/N=3).,Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12798189/),,3,134589,DB00182,Amphetamine
,19663523,terminal elimination half-life,"Armodafinil and modafinil both had a mean single-dose terminal elimination half-life of approximately 13 hours, with similar mean maximum plasma drug concentration (C(max)) and median time to C(max) values.","Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19663523/),h,13,135179,DB00182,Amphetamine
,22039171,maximal plasma concentration (C(max)),"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),[ng] / [ml],37.6,135862,DB00182,Amphetamine
,22039171,maximal plasma concentration (C(max)),"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),[ng] / [ml],40.5,135863,DB00182,Amphetamine
,22039171,maximal plasma concentration (C(max)),"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),[ng] / [ml],38.7,135864,DB00182,Amphetamine
,22039171,maximal plasma concentration (C(max)),"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),[ng] / [ml],25.7,135865,DB00182,Amphetamine
,22039171,area under the concentration-time curve to the last measurable time point,"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h·ml⁻¹·ng,719.1,135866,DB00182,Amphetamine
,22039171,area under the concentration-time curve to the last measurable time point,"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h·ml⁻¹·ng,771.2,135867,DB00182,Amphetamine
,22039171,area under the concentration-time curve to the last measurable time point,"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h·ml⁻¹·ng,752.4,135868,DB00182,Amphetamine
,22039171,area under the concentration-time curve to the last measurable time point,"Mean (S.D.) maximal plasma concentration (C(max)) was 37.6 (4.54), 40.5 (4.95), 38.7 (6.46), and 25.7 (9.07) ng/ml; area under the concentration-time curve to the last measurable time point was 719.1 (157.05), 771.2 (152.88), 752.4 (163.38), and 574.3 (220.65) ng · h · ml⁻¹, respectively, for d-amphetamine after oral, PSB, DSB, and AC delivery of LDX.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h·ml⁻¹·ng,574.3,135869,DB00182,Amphetamine
,22039171,time to C(max),"Median time to C(max) was 5, 4, 5, and 8 h, respectively.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h,5,135870,DB00182,Amphetamine
,22039171,time to C(max),"Median time to C(max) was 5, 4, 5, and 8 h, respectively.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h,4,135871,DB00182,Amphetamine
,22039171,time to C(max),"Median time to C(max) was 5, 4, 5, and 8 h, respectively.",Pharmacokinetics of lisdexamfetamine dimesylate after targeted gastrointestinal release or oral administration in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22039171/),h,8,135872,DB00182,Amphetamine
,18021493,steady-state d,"Based on C(min), steady-state d-amphetamine concentration (20.6 ng/mL) was reached by day 5, whereas LDX was undetectable, and 95% of the d-amphetamine was eliminated within 48 hours following the final dose on day 7.",Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021493/),[ng] / [ml],20.6,137648,DB00182,Amphetamine
,18021493,C(max),"At steady state, d-amphetamine achieved a mean +/- standard deviation C(max) of 90.1 +/- 29.6 ng/mL, with a median T(max) of 3.0 hours.",Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021493/),[ng] / [ml],90.1,137649,DB00182,Amphetamine
,18021493,T(max),"At steady state, d-amphetamine achieved a mean +/- standard deviation C(max) of 90.1 +/- 29.6 ng/mL, with a median T(max) of 3.0 hours.",Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021493/),h,3.0,137650,DB00182,Amphetamine
,18021493,AUC(0-inf),The AUC(0-inf) for d-amphetamine was 1453 +/- 645.7 ng.h/mL.,Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18021493/),[h·ng] / [ml],1453,137651,DB00182,Amphetamine
,26452730,half-life,The half-life values for MA in the breast milk were 11.3 and 40.3 hours.,Transfer of Methamphetamine (MA) into Breast Milk and Urine of Postpartum Women who Smoked MA Tablets during Pregnancy: Implications for Initiation of Breastfeeding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26452730/),h,11.3,140725,DB00182,Amphetamine
,26452730,half-life,The half-life values for MA in the breast milk were 11.3 and 40.3 hours.,Transfer of Methamphetamine (MA) into Breast Milk and Urine of Postpartum Women who Smoked MA Tablets during Pregnancy: Implications for Initiation of Breastfeeding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26452730/),h,40.3,140726,DB00182,Amphetamine
,25484042,half-life,"Ch-mAb7F9 displayed expected IgG pharmacokinetic parameters, including a half-life of 17-19 d in the 3 highest dose groups and volume of distribution of 5-6 L, suggesting the antibody is confined primarily to the vascular compartment.",First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484042/),d,17-19,141875,DB00182,Amphetamine
,25484042,volume of distribution,"Ch-mAb7F9 displayed expected IgG pharmacokinetic parameters, including a half-life of 17-19 d in the 3 highest dose groups and volume of distribution of 5-6 L, suggesting the antibody is confined primarily to the vascular compartment.",First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484042/),l,5-6,141876,DB00182,Amphetamine
,10682227,half-lives,"However, the half-lives of selegiline (range, 1.5-3.5 h) and desmethylselegiline (range, 3.4-5.3 h) were found to be relatively short.",Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682227/),h,1.5-3.5,143558,DB00182,Amphetamine
,10682227,half-lives,"However, the half-lives of selegiline (range, 1.5-3.5 h) and desmethylselegiline (range, 3.4-5.3 h) were found to be relatively short.",Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682227/),h,3.4-5.3,143559,DB00182,Amphetamine
,11699608,Elimination half-life,Elimination half-life was approximately 6 h.,Pharmacodynamics and pharmacokinetics of single nasal (5 mg and 10 mg) and oral (50 mg) doses of ephedrine in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699608/),h,6,144104,DB00182,Amphetamine
,10381769,Cmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),[ng] / [ml],236.4,146037,DB00182,Amphetamine
,10381769,Cmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),[ng] / [ml],130.9,146038,DB00182,Amphetamine
,10381769,Tmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,2.4,146039,DB00182,Amphetamine
,10381769,Tmax,"Cmax values for 125-mg and 75-mg MDMA doses were 236.4 and 130.9 ng/ml, and Tmax was observed at 2.4 and 1.8 h, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,1.8,146040,DB00182,Amphetamine
,10381769,Elimination half-life,"Elimination half-life was 8.6 h and 7.7 h for high and low MDMA doses, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,8.6,146041,DB00182,Amphetamine
,10381769,Elimination half-life,"Elimination half-life was 8.6 h and 7.7 h for high and low MDMA doses, respectively.","Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,7.7,146042,DB00182,Amphetamine
,10381769,half-life,Amphetamine half-life was 15 h.,"Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381769/),h,15,146043,DB00182,Amphetamine
,25804420,plasma half-life,3-MMC displayed rapid absorption with a peak concentration achieved within 5-10 min after oral ingestion and a plasma half-life of 0.8 h.,3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25804420/),h,0.8,146241,DB00182,Amphetamine
,25804420,bioavailability,The bioavailability was about 7%.,3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25804420/),%,7,146242,DB00182,Amphetamine
,17127110,CL(int),"For PMMA, the SS experiment resulted in a CL(int) of 2.7+/-0.2 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 3.0+/-0.6 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],2.7,146251,DB00182,Amphetamine
,17127110,CL(int),"For PMMA, the SS experiment resulted in a CL(int) of 2.7+/-0.2 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 3.0+/-0.6 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],3.0,146252,DB00182,Amphetamine
,17127110,CL(int),"For fluoxetine, the SS experiment resulted in a CL(int) of 0.33+/-0.17 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 0.188+/-0.013 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],0.33,146253,DB00182,Amphetamine
,17127110,CL(int),"For fluoxetine, the SS experiment resulted in a CL(int) of 0.33+/-0.17 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 0.188+/-0.013 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],0.188,146254,DB00182,Amphetamine
< or =,17982891,t1/2beta,The peak concentrations (C(max)) were reached at 15 min after treatment and the absorption was followed by a fast elimination (t1/2beta < or = 2h).,Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982891/),h,2,146749,DB00182,Amphetamine
,17982891,bioavailability,Increased bioavailability was detected after subcutaneous (87.1%) and intraperitoneal (78.7%) administration.,Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982891/),%,87.1,146750,DB00182,Amphetamine
,17982891,bioavailability,Increased bioavailability was detected after subcutaneous (87.1%) and intraperitoneal (78.7%) administration.,Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982891/),%,78.7,146751,DB00182,Amphetamine
,10388483,plasma half-life,"The plasma concentrations of (R)-MDMA exceeded those of the S-enantiomer [ratio R:S of the area under the curve (AUC), 2.4 +/- 0.3], and the plasma half-life of (R)-MDMA (5.8 +/- 2.2 h) was significantly longer than that of the S-enantiomer (3.6 +/- 0.9 h).","Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388483/),h,5.8,148701,DB00182,Amphetamine
,10388483,plasma half-life,"The plasma concentrations of (R)-MDMA exceeded those of the S-enantiomer [ratio R:S of the area under the curve (AUC), 2.4 +/- 0.3], and the plasma half-life of (R)-MDMA (5.8 +/- 2.2 h) was significantly longer than that of the S-enantiomer (3.6 +/- 0.9 h).","Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388483/),h,3.6,148702,DB00182,Amphetamine
,10388483,recovery,"The majority of the recovered material in urine was excreted within 24 h after dosing, with the recovery of (R)-MDMA (21.4% +/- 11.6%) being significantly greater than that of (S)-MDMA (9.3% +/- 4.9%), and with (S)- and (R)-MDA accounting for 1.4% +/- 0.5% and 1.0% +/- 0.3% of the dose, respectively.","Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388483/),%,21.4,148703,DB00182,Amphetamine
,10388483,recovery,"The majority of the recovered material in urine was excreted within 24 h after dosing, with the recovery of (R)-MDMA (21.4% +/- 11.6%) being significantly greater than that of (S)-MDMA (9.3% +/- 4.9%), and with (S)- and (R)-MDA accounting for 1.4% +/- 0.5% and 1.0% +/- 0.3% of the dose, respectively.","Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10388483/),%,9.3,148704,DB00182,Amphetamine
,9243353,time to reach maximal inhibition [tmax],"The maximal inhibition by desmethylselegiline was reached significantly later after desmethylselegiline (time to reach maximal inhibition [tmax], 27 +/- 20 hours) than after selegiline administration (tmax, 1.4 +/- 1.4 hours).","Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243353/),h,27,149858,DB00182,Amphetamine
,9243353,tmax,"The maximal inhibition by desmethylselegiline was reached significantly later after desmethylselegiline (time to reach maximal inhibition [tmax], 27 +/- 20 hours) than after selegiline administration (tmax, 1.4 +/- 1.4 hours).","Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243353/),h,1.4,149859,DB00182,Amphetamine
,14586388,bioavailabilities,"Methamphetamine was well absorbed after smoking or intranasal administration, with bioavailabilities of 79% after intranasal administration and 67% of the estimated delivered dose or 37.4% of the absolute (pipe) dose after smoking.",The bioavailability of intranasal and smoked methamphetamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),%,79,151609,DB00182,Amphetamine
,14586388,bioavailabilities,"Methamphetamine was well absorbed after smoking or intranasal administration, with bioavailabilities of 79% after intranasal administration and 67% of the estimated delivered dose or 37.4% of the absolute (pipe) dose after smoking.",The bioavailability of intranasal and smoked methamphetamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),%,67,151610,DB00182,Amphetamine
,14586388,bioavailabilities,"Methamphetamine was well absorbed after smoking or intranasal administration, with bioavailabilities of 79% after intranasal administration and 67% of the estimated delivered dose or 37.4% of the absolute (pipe) dose after smoking.",The bioavailability of intranasal and smoked methamphetamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),%,37.4,151611,DB00182,Amphetamine
,14586388,elimination half-life,"The elimination half-life was similar for intravenous (11.4 hours), intranasal (10.7 hours), and smoked (10.7 hours) methamphetamine.",The bioavailability of intranasal and smoked methamphetamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,11.4,151612,DB00182,Amphetamine
,14586388,elimination half-life,"The elimination half-life was similar for intravenous (11.4 hours), intranasal (10.7 hours), and smoked (10.7 hours) methamphetamine.",The bioavailability of intranasal and smoked methamphetamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,10.7,151613,DB00182,Amphetamine
,14586388,Clearance,"Clearance (272 mL x h(-1) x kg(-1)), steady-state volume of distribution (4.2 L/kg), and mean residence time (16 hours) of the intravenous dose were similar to previously reported values.",The bioavailability of intranasal and smoked methamphetamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[ml] / [h·kg],272,151614,DB00182,Amphetamine
,14586388,steady-state volume of distribution,"Clearance (272 mL x h(-1) x kg(-1)), steady-state volume of distribution (4.2 L/kg), and mean residence time (16 hours) of the intravenous dose were similar to previously reported values.",The bioavailability of intranasal and smoked methamphetamine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[l] / [kg],4.2,151615,DB00182,Amphetamine
,14586388,mean residence time,"Clearance (272 mL x h(-1) x kg(-1)), steady-state volume of distribution (4.2 L/kg), and mean residence time (16 hours) of the intravenous dose were similar to previously reported values.",The bioavailability of intranasal and smoked methamphetamine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,16,151616,DB00182,Amphetamine
,14586388,half-life,"Dextroamphetamine (INN, dexamfetamine) half-life (all routes) was 16.2 hours.",The bioavailability of intranasal and smoked methamphetamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,16.2,151617,DB00182,Amphetamine
,14586388,renal clearances,"Methamphetamine and dextroamphetamine renal clearances (all routes) were about 100 and 1100 mL x h(-1) x kg(-1), respectively.",The bioavailability of intranasal and smoked methamphetamine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[ml] / [h·kg],100,151618,DB00182,Amphetamine
,14586388,renal clearances,"Methamphetamine and dextroamphetamine renal clearances (all routes) were about 100 and 1100 mL x h(-1) x kg(-1), respectively.",The bioavailability of intranasal and smoked methamphetamine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[ml] / [h·kg],1100,151619,DB00182,Amphetamine
,10688621,terminal elimination half-life,"Based on data from the area under the concentration-time curves after i.v. dosing, the rank order of (+)-METH tissue accumulation was kidney > spleen > brain > liver > heart > serum with terminal elimination half-life values ranging from 53 to 66 min.",Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688621/),min,53 to 66,152475,DB00182,Amphetamine
,10688621,brain-to-serum concentration ratio,The brain-to-serum concentration ratio rose from 7:1 at 2 min to a peak of 13:1 at 20 min before equilibrating to a constant value of 8:1 at 2 h.,Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688621/),,7:1,152476,DB00182,Amphetamine
,10688621,brain-to-serum concentration ratio,The brain-to-serum concentration ratio rose from 7:1 at 2 min to a peak of 13:1 at 20 min before equilibrating to a constant value of 8:1 at 2 h.,Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688621/),,13:1,152477,DB00182,Amphetamine
,10688621,brain-to-serum concentration ratio,The brain-to-serum concentration ratio rose from 7:1 at 2 min to a peak of 13:1 at 20 min before equilibrating to a constant value of 8:1 at 2 h.,Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688621/),,8,152478,DB00182,Amphetamine
,10688621,terminal elimination half-life,(+)-AMP concentrations peaked at 20 min in all tissues before decaying with terminal elimination half-life values ranging from 68 to 75 min.,Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688621/),min,68 to 75,152479,DB00182,Amphetamine
,30911906,time to maximum plasma concentration,"Consuming a high-fat meal prolonged median time to maximum plasma concentration for d- and l-amphetamine by 5.0 and 4.5 h, respectively, relative to reference treatment.",Effects of Food on the Bioavailability of Amphetamine in Healthy Adults After Administration of SHP465 Mixed Amphetamine Salts Extended-Release Capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30911906/),h,5.0,154400,DB00182,Amphetamine
,30911906,time to maximum plasma concentration,"Consuming a high-fat meal prolonged median time to maximum plasma concentration for d- and l-amphetamine by 5.0 and 4.5 h, respectively, relative to reference treatment.",Effects of Food on the Bioavailability of Amphetamine in Healthy Adults After Administration of SHP465 Mixed Amphetamine Salts Extended-Release Capsules. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30911906/),h,4.5,154401,DB00182,Amphetamine
,12921476,Time to maximum concentration (Tmax),"Time to maximum concentration (Tmax) for SLI381 versus Adderall showed average increases of 3.0 hours for dextroamphetamine (t = -2.35, p = .04, df = 8.6) and 3.2 hours for levoamphetamine (t = -2.39, p = .04, df = 9.2).","Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12921476/),h,3.0,155763,DB00182,Amphetamine
,12921476,Time to maximum concentration (Tmax),"Time to maximum concentration (Tmax) for SLI381 versus Adderall showed average increases of 3.0 hours for dextroamphetamine (t = -2.35, p = .04, df = 8.6) and 3.2 hours for levoamphetamine (t = -2.39, p = .04, df = 9.2).","Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12921476/),h,3.2,155764,DB00182,Amphetamine
>,11916012,peak resolution,Each enantiomer of MBDB and BDB was monitored (peak resolution > 1.00) by HPLC analysis within 30 min.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),,1.00,156420,DB00182,Amphetamine
,11916012,urinary excretion,The urinary excretion of MBDB showed significant difference between the two enantiomers from 4 to 20 h (p < 0.05).,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),h,4,156421,DB00182,Amphetamine
,11916012,amount,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,34,156422,DB00182,Amphetamine
,11916012,amount,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,17.6,156423,DB00182,Amphetamine
,11916012,amount,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,17.1,156424,DB00182,Amphetamine
,11916012,excreted,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,34,156425,DB00182,Amphetamine
,11916012,excreted,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,17.6,156426,DB00182,Amphetamine
,11916012,excreted,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,17.1,156427,DB00182,Amphetamine
,11916012,amount,The amount of BDB was 4.9+/-1.0%; 2.9+/-0.6% for (+)-isomer and 2.0+/-0.4% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),,4,156428,DB00182,Amphetamine
,11916012,amount,The amount of BDB was 4.9+/-1.0%; 2.9+/-0.6% for (+)-isomer and 2.0+/-0.4% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,2.9,156429,DB00182,Amphetamine
,11916012,amount,The amount of BDB was 4.9+/-1.0%; 2.9+/-0.6% for (+)-isomer and 2.0+/-0.4% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,2.0,156430,DB00182,Amphetamine
,29740356,brain/serum ratio,"We also established a MDPV brain/serum ratio ~2 lasting for ~120 min, consistent with our behavioural observations of locomotor activation and disrupted spatial distribution of behaviour as well as moderate increases in body temperature (exacerbated in group-housed animals).","Behavioural, Pharmacokinetic, Metabolic, and Hyperthermic Profile of 3,4-Methylenedioxypyrovalerone (MDPV) in the Wistar Rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29740356/),,2,158967,DB00182,Amphetamine
,12657914,limits of detection,The limits of detection (0.01 microg/mL) and quantitation (0.5 microg/mL) were well below the concentration expected in serum from patients receiving therapeutic doses of modafinil.,Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657914/),[μg] / [ml],0.01,159323,DB00182,Amphetamine
,18339493,half-life,The disposition of 2C-B was characterized by its estimated half-life 1.1h and estimated volume of distribution 16L/kg.,"Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339493/),h,1.1,162187,DB00182,Amphetamine
,18339493,volume of distribution,The disposition of 2C-B was characterized by its estimated half-life 1.1h and estimated volume of distribution 16L/kg.,"Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339493/),[l] / [kg],16,162188,DB00182,Amphetamine
,18339493,brain to serum ratio,2C-B brain to serum ratio attained a maximum value of 13.9 and remained over the value of 6.5 to the end of our observation (6h after the dose).,"Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339493/),,13.9,162189,DB00182,Amphetamine
,18339493,brain to serum ratio,2C-B brain to serum ratio attained a maximum value of 13.9 and remained over the value of 6.5 to the end of our observation (6h after the dose).,"Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18339493/),,6.5,162190,DB00182,Amphetamine
,20233182,excretion,"Correspondingly, S-(+)-MA excretion was less than R-(-)-MA (42% vs. 52%; P= 0.005).",Stereoselectivity in the human metabolism of methamphetamine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233182/),%,42,163689,DB00182,Amphetamine
,20233182,excretion,"Correspondingly, S-(+)-MA excretion was less than R-(-)-MA (42% vs. 52%; P= 0.005).",Stereoselectivity in the human metabolism of methamphetamine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233182/),%,52,163690,DB00182,Amphetamine
,8097698,net output,The net output of lactate from the hindquarter over 12 hr following drug administration was calculated to be 6.25 +/- 1.35 g (0.07 +/- 0.015 mol).,"Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),g,6.25,166654,DB00182,Amphetamine
,8097698,net output,The net output of lactate from the hindquarter over 12 hr following drug administration was calculated to be 6.25 +/- 1.35 g (0.07 +/- 0.015 mol).,"Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),mol,0.07,166655,DB00182,Amphetamine
,8097698,cumulative urinary excretion,"The cumulative urinary excretion of labetalol as unchanged drug, glucuronide and sulfate was found to be 1.61 +/- 0.3, 11.46 +/- 2.83, and 1.47 +/- 0.74% of the dose, respectively.","Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),%,1.61,166656,DB00182,Amphetamine
,8097698,cumulative urinary excretion,"The cumulative urinary excretion of labetalol as unchanged drug, glucuronide and sulfate was found to be 1.61 +/- 0.3, 11.46 +/- 2.83, and 1.47 +/- 0.74% of the dose, respectively.","Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),%,11.46,166657,DB00182,Amphetamine
,8097698,cumulative urinary excretion,"The cumulative urinary excretion of labetalol as unchanged drug, glucuronide and sulfate was found to be 1.61 +/- 0.3, 11.46 +/- 2.83, and 1.47 +/- 0.74% of the dose, respectively.","Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),%,1.47,166658,DB00182,Amphetamine
,8097698,apparent elimination half-life,Pharmacokinetic analysis shows the apparent elimination half-life of the metabolite to be 13.5 +/- 3.8 min.,"Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),min,13.5,166659,DB00182,Amphetamine
,26159352,KD,We found that the high affinity (KD = 6.2 nM) and specificity for METH was unchanged after nanoparticle conjugation.,A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26159352/),nM,6.2,167403,DB00182,Amphetamine
,26159352,half-life,"We have thus successfully developed a novel multivalent METH-binding nanomedicine by conjugating multiple anti-METH scFvs to dendrimer nanoparticles, extending the scFv half-life from 1.3 (± 0.3) to 26 (± 2.6) hr.",A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26159352/),h,1.3,167404,DB00182,Amphetamine
,26159352,half-life,"We have thus successfully developed a novel multivalent METH-binding nanomedicine by conjugating multiple anti-METH scFvs to dendrimer nanoparticles, extending the scFv half-life from 1.3 (± 0.3) to 26 (± 2.6) hr.",A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26159352/),h,26,167405,DB00182,Amphetamine
,26329917,Absorption rate constant,"Absorption rate constant, clearance, and volume of distribution for the plasma compartment were estimated as 0.527 h(-1) (95% CI 0.467-0.586), 28.7 L/h (95% CI 27.1-30.3), and 377 L (95% CI 326-428), respectively.",A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329917/),1/[h],0.527,172150,DB00182,Amphetamine
,26329917,clearance,"Absorption rate constant, clearance, and volume of distribution for the plasma compartment were estimated as 0.527 h(-1) (95% CI 0.467-0.586), 28.7 L/h (95% CI 27.1-30.3), and 377 L (95% CI 326-428), respectively.",A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329917/),[l] / [h],28.7,172151,DB00182,Amphetamine
,26329917,volume of distribution for the,"Absorption rate constant, clearance, and volume of distribution for the plasma compartment were estimated as 0.527 h(-1) (95% CI 0.467-0.586), 28.7 L/h (95% CI 27.1-30.3), and 377 L (95% CI 326-428), respectively.",A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329917/),l,377,172152,DB00182,Amphetamine
,26329917,incorporation rate constant,The incorporation rate constant from plasma to hair was 1.60e(-6) h(-1) (95% CI 1.06e(-6)-2.14e(-6)) and apparent volume of distribution in hair was 17.7 mg (95% CI 12.5-22.8).,A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329917/),1/[(e)^6·h],1.60,172153,DB00182,Amphetamine
,26329917,apparent volume of distribution,The incorporation rate constant from plasma to hair was 1.60e(-6) h(-1) (95% CI 1.06e(-6)-2.14e(-6)) and apparent volume of distribution in hair was 17.7 mg (95% CI 12.5-22.8).,A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26329917/),mg,17.7,172154,DB00182,Amphetamine
,7120117,half-lives,The plasma pharmacokinetics of both PEA and NMPEA could be described by first-order kinetics which estimated half-lives of approximately 5 to 10 min.,Physiologic effects and plasma kinetics of beta-phenylethylamine and its N-methyl homolog in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120117/),min,5 to 10,174110,DB00182,Amphetamine
,24839971,equilibrium dissociation rate constant (KD),We hypothesized that treatment of pregnant rat dams with a dual reactive monoclonal antibody (mAb4G9) against (+)-methamphetamine [METH; equilibrium dissociation rate constant (KD) = 16 nM] and (+)-amphetamine (AMP; KD = 102 nM) could confer maternal and fetal protection from brain accumulation of both drugs of abuse.,Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839971/),nM,16,176519,DB00182,Amphetamine
,24839971,KD,We hypothesized that treatment of pregnant rat dams with a dual reactive monoclonal antibody (mAb4G9) against (+)-methamphetamine [METH; equilibrium dissociation rate constant (KD) = 16 nM] and (+)-amphetamine (AMP; KD = 102 nM) could confer maternal and fetal protection from brain accumulation of both drugs of abuse.,Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839971/),nM,102,176520,DB00182,Amphetamine
,16123749,half-life,"We developed a computer-controlled intravenous methamphetamine (METH) administration procedure (dynamic infusion), which enables us to compensate for an important pharmacokinetic difference between rats and humans by imposing a 12-h half-life for the drug in rats.",Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123749/),h,12,177784,DB00182,Amphetamine
,16123749,apparent half-life,"Dynamic infusion of 0.5 mg/kg METH produced a pharmacokinetic profile that closely simulates the METH exposure pattern in humans, including an apparent half-life of 11.6+/-1.3 h, and an area under the concentration vs time curve of 9.4 microM h, about 20-fold larger than results obtained with typical rat pharmacokinetics.",Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123749/),h,11.6,177785,DB00182,Amphetamine
,16123749,area under the concentration vs time curve,"Dynamic infusion of 0.5 mg/kg METH produced a pharmacokinetic profile that closely simulates the METH exposure pattern in humans, including an apparent half-life of 11.6+/-1.3 h, and an area under the concentration vs time curve of 9.4 microM h, about 20-fold larger than results obtained with typical rat pharmacokinetics.",Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123749/),h·μM,9.4,177786,DB00182,Amphetamine
over,18396472,recoveries,The recoveries were over 90% in all biological samples tested.,"Analysis of amphetamine-type stimulants and their metabolites in plasma, urine and bile by liquid chromatography with a strong cation-exchange column-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18396472/),%,90,178357,DB00182,Amphetamine
,8070317,systemic,"The systemic and renal clearances, steady-state volume of distribution, and terminal half-life for l-AP were (mean +/- SD), respectively: 65.6 +/- 9.25 ml/min.kg; 15.4 +/- 2.55 ml/min.kg; 4.33 +/- 0.71 liters/kg; and 0.96 +/- 0.13 hr.",Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070317/),[ml] / [kg·min],65.6,179077,DB00182,Amphetamine
,8070317,renal clearances,"The systemic and renal clearances, steady-state volume of distribution, and terminal half-life for l-AP were (mean +/- SD), respectively: 65.6 +/- 9.25 ml/min.kg; 15.4 +/- 2.55 ml/min.kg; 4.33 +/- 0.71 liters/kg; and 0.96 +/- 0.13 hr.",Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070317/),[ml] / [kg·min],65.6,179078,DB00182,Amphetamine
,8070317,steady-state volume of distribution,"The systemic and renal clearances, steady-state volume of distribution, and terminal half-life for l-AP were (mean +/- SD), respectively: 65.6 +/- 9.25 ml/min.kg; 15.4 +/- 2.55 ml/min.kg; 4.33 +/- 0.71 liters/kg; and 0.96 +/- 0.13 hr.",Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070317/),[ml] / [kg·min],15.4,179079,DB00182,Amphetamine
,8070317,steady-state volume of distribution,"The systemic and renal clearances, steady-state volume of distribution, and terminal half-life for l-AP were (mean +/- SD), respectively: 65.6 +/- 9.25 ml/min.kg; 15.4 +/- 2.55 ml/min.kg; 4.33 +/- 0.71 liters/kg; and 0.96 +/- 0.13 hr.",Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070317/),[l] / [kg],4.33,179080,DB00182,Amphetamine
,8070317,terminal half-life,"The systemic and renal clearances, steady-state volume of distribution, and terminal half-life for l-AP were (mean +/- SD), respectively: 65.6 +/- 9.25 ml/min.kg; 15.4 +/- 2.55 ml/min.kg; 4.33 +/- 0.71 liters/kg; and 0.96 +/- 0.13 hr.",Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070317/),h,0.96,179081,DB00182,Amphetamine
,23257312,c,The pharmacokinetic analysis of ADX71743 in mice and rats revealed that it is bioavailable after s.c. administration and is brain penetrant (cerebrospinal fluid concentration/total plasma concentration ratio at C(max) = 5.3%).,"ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23257312/),%,5.3,181693,DB00182,Amphetamine
,25668796,flow rate,"Analyses were performed on a liquid chromatography system employing a Kromasil 60-5CN column (2.1 mm × 100 mm, 5 μm) and an isocratic elution with mixed solution of acetonitrile-20mM ammonium formate containing 0.3% formic acid (40:60, v/v), at a flow rate of 0.35 mL/min.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),[ml] / [min],0.35,182760,DB00182,Amphetamine
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,452.1,182761,DB00182,Amphetamine
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,344.3,182762,DB00182,Amphetamine
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,338.3,182763,DB00182,Amphetamine
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,77.9,182764,DB00182,Amphetamine
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,355.0,182765,DB00182,Amphetamine
,25668796,m/z,"The determination was carried out on an API 4000 triple-quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) mode using the following transitions monitored simultaneously: positive m/z 150.0/91.0 for phentermine, m/z 452.1/344.3 for doxazosin, and negative m/z 338.3/77.9 for topiramate, m/z 355.0/41.9 for pioglitazone.",Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25668796/),,41.9,182766,DB00182,Amphetamine
,11862265,Trough levels,Trough levels of 3.3 and 6.0 ng / mL for L-amphetamine and L-methamphetamine suggest that steady state was achieved by the third dosing day for these metabolites.,"The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),[ng] / [ml],3.3,184467,DB00182,Amphetamine
,11862265,Trough levels,Trough levels of 3.3 and 6.0 ng / mL for L-amphetamine and L-methamphetamine suggest that steady state was achieved by the third dosing day for these metabolites.,"The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),[ng] / [ml],6.0,184468,DB00182,Amphetamine
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,8.6,184469,DB00182,Amphetamine
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,9.5,184470,DB00182,Amphetamine
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,1.5,184471,DB00182,Amphetamine
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,3.8,184472,DB00182,Amphetamine
,111276,apparent elimination half-life,"Sixteen male children who scored greater than 2SD from norms on Factors I and IV of Conner's Teacher Rating Scale and who were not excluded for reasons to do with medical or psychiatric conditions, intelligence, or age, had a plasma d-amphetamine apparent elimination half-life of 6.8 +/- 0.5h.",Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/111276/),h,6.8,185735,DB00182,Amphetamine
,111276,Peak plasma level,"Peak plasma level occurred between 3 and 4h (62.7 +/- 3.8 and 65.9 +/- 3.6 ng/ml, respectively).",Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/111276/),[ng] / [ml],62.7,185736,DB00182,Amphetamine
,111276,Peak plasma level,"Peak plasma level occurred between 3 and 4h (62.7 +/- 3.8 and 65.9 +/- 3.6 ng/ml, respectively).",Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/111276/),[ng] / [ml],65.9,185737,DB00182,Amphetamine
,20206783,C(max),"Mean (%CV) C(max) values of d-amphetamine postdose were 53.2 (18.1), 93.3 (19.5), and 134.0 (19.4) ng/mL with LDX 30, 50, and 70 mg, respectively (T(max), approximately 3.5 hours).","Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206783/),[ng] / [ml],53.2,187017,DB00182,Amphetamine
,20206783,C(max),"Mean (%CV) C(max) values of d-amphetamine postdose were 53.2 (18.1), 93.3 (19.5), and 134.0 (19.4) ng/mL with LDX 30, 50, and 70 mg, respectively (T(max), approximately 3.5 hours).","Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206783/),[ng] / [ml],93.3,187018,DB00182,Amphetamine
,20206783,C(max),"Mean (%CV) C(max) values of d-amphetamine postdose were 53.2 (18.1), 93.3 (19.5), and 134.0 (19.4) ng/mL with LDX 30, 50, and 70 mg, respectively (T(max), approximately 3.5 hours).","Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206783/),[ng] / [ml],134.0,187019,DB00182,Amphetamine
,20206783,T(max),"Mean (%CV) C(max) values of d-amphetamine postdose were 53.2 (18.1), 93.3 (19.5), and 134.0 (19.4) ng/mL with LDX 30, 50, and 70 mg, respectively (T(max), approximately 3.5 hours).","Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20206783/),h,3.5,187020,DB00182,Amphetamine
,27798075,Peak plasma concentration (Cmax,Peak plasma concentration (Cmax = 122.6 ± 32.9 ng/mL) was reached at 1 hour (0.5-2 h) post-drug administration.,GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798075/),[ng] / [ml],122.6,187129,DB00182,Amphetamine
,27798075,elimination half-life (t1/2,Mephedrone showed a rapid elimination half-life (t1/2 = 2.2 h) compared to other psychostimulants.,GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human Pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798075/),h,2.2,187130,DB00182,Amphetamine
,3790195,peak excretion time,"Excepting a shift in the peak excretion time to 4-5 h, no meaningful pharmacokinetic differences were found when Apetinil-Depot, a retard formulation, was administered.",The influence of diuretics on the excretion and metabolism of doping agents. Etilamfetamine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790195/),h,4-5,195425,DB00182,Amphetamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],348.0,195990,DB00182,Amphetamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],68,195991,DB00182,Amphetamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,29.,195992,DB00182,Amphetamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,243,195993,DB00182,Amphetamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],401.8,195994,DB00182,Amphetamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],671.1,195995,DB00182,Amphetamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,159.9,195996,DB00182,Amphetamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,243.4,195997,DB00182,Amphetamine
,2725116,limit of detection,"The limit of detection of nicotine in plasma was around 1 ng/ml and that of nicotine and cotinine in urine around 20 ng/ml and 10 ng/ml, respectively.","High performance liquid chromatographic determination of nicotine and cotinine in plasma and nicotine and cotinine, simultaneously, in urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2725116/),[ng] / [ml],1,196638,DB00182,Amphetamine
,2725116,limit of detection,"The limit of detection of nicotine in plasma was around 1 ng/ml and that of nicotine and cotinine in urine around 20 ng/ml and 10 ng/ml, respectively.","High performance liquid chromatographic determination of nicotine and cotinine in plasma and nicotine and cotinine, simultaneously, in urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2725116/),[ng] / [ml],20,196639,DB00182,Amphetamine
,2725116,limit of detection,"The limit of detection of nicotine in plasma was around 1 ng/ml and that of nicotine and cotinine in urine around 20 ng/ml and 10 ng/ml, respectively.","High performance liquid chromatographic determination of nicotine and cotinine in plasma and nicotine and cotinine, simultaneously, in urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2725116/),[ng] / [ml],10,196640,DB00182,Amphetamine
,12394422,K(D),"Animals were trained to discriminate 5 or 10 mg/kg cocaine (rats), or 3 mg/kg (+)-amphetamine (pigeons) from saline, after which dose-response curves were determined for (+)-methamphetamine and other drugs before and after administration of a (+)-methamphetamine-specific monoclonal antibody (K(D) =250 nM).",Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394422/),nM,250,198525,DB00182,Amphetamine
,25271258,brain-to-plasma ratio,"In this study, we characterized JNJ-42253432 [2-methyl-N-([1-(4-phenylpiperazin-1-yl)cyclohexyl]methyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide] as a centrally permeable (brain-to-plasma ratio of 1), high-affinity P2X7 antagonist with desirable pharmacokinetic and pharmacodynamic properties for in vivo testing in rodents.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,1,200086,DB00182,Amphetamine
,25271258,p,JNJ-42253432 is a high-affinity antagonist for the rat (pKi 9.1 ± 0.07) and human (pKi 7.9 ± 0.08) P2X7 channel.,Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,9.1,200087,DB00182,Amphetamine
,25271258,p,JNJ-42253432 is a high-affinity antagonist for the rat (pKi 9.1 ± 0.07) and human (pKi 7.9 ± 0.08) P2X7 channel.,Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),,7.9,200088,DB00182,Amphetamine
,25271258,ED50,"When dosed in rats, JNJ-42253432 occupied the brain P2X7 channel with an ED50 of 0.3 mg/kg, corresponding to a mean plasma concentration of 42 ng/ml.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),[mg] / [kg],0.3,200089,DB00182,Amphetamine
,25271258,ED50,"At higher doses/exposure, JNJ-42253432 also increased serotonin levels in the rat brain, which is due to antagonism of the serotonin transporter (SERT) resulting in an ED50 of 10 mg/kg for SERT occupancy.",Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25271258/),[mg] / [kg],10,200090,DB00182,Amphetamine
,23363010,T1/2,Pharmacokinetic studies found that the T1/2 of 4-MMC was about 1 hour in vivo in rat plasma and 90 minutes using in vitro liver microsomal assays.,Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363010/),h,1,201357,DB00182,Amphetamine
,23363010,T1/2,Pharmacokinetic studies found that the T1/2 of 4-MMC was about 1 hour in vivo in rat plasma and 90 minutes using in vitro liver microsomal assays.,Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363010/),min,90,201358,DB00182,Amphetamine
,15999148,half-life,"Oral MDMA administration engendered a plasma profile of MDMA in squirrel monkeys resembling that seen in humans, although the half-life of MDMA in monkeys is shorter (3 vs 6-9 h).",Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15999148/),h,3,202858,DB00182,Amphetamine
,15999148,half-life,"Oral MDMA administration engendered a plasma profile of MDMA in squirrel monkeys resembling that seen in humans, although the half-life of MDMA in monkeys is shorter (3 vs 6-9 h).",Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15999148/),h,6-9,202859,DB00182,Amphetamine
,15999148,plasma ratio,"MDMA was biotransformed into MDA, and the plasma ratio of MDA to MDMA was 3-5 / 100, similar to that in humans.",Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15999148/),,3-5,202860,DB00182,Amphetamine
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],6.5,204252,DB00182,Amphetamine
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],14.7,204253,DB00182,Amphetamine
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],0.9,204254,DB00182,Amphetamine
,2515726,recovery,"The metabolites of selegiline were excreted in urine, and the recovery as metabolites was 87%.",Pharmacokinetics and metabolism of selegiline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),%,87,204255,DB00182,Amphetamine
,12088728,recovery coefficient,The recovery coefficient of unmetabolized R(-)[123I]DOI was 68%.,"Pharmacokinetics and brain distribution in non human primate of R(-)[123I]DOI, A 5HT(2A/2C) serotonin agonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088728/),%,68,205193,DB00182,Amphetamine
,12088728,Free fraction determination (f(1)),"Free fraction determination (f(1)), was 31 +/- 0.9% (n = 3).","Pharmacokinetics and brain distribution in non human primate of R(-)[123I]DOI, A 5HT(2A/2C) serotonin agonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088728/),%,31,205194,DB00182,Amphetamine
,9021435,elimination half-life,"As plasma levels of selegiline are very low and the elimination half-life is very short being about 9 minutes, therefore, a very sensitive and selective method for determining the 3 main metabolites desmethylselegiline (DMS), methamphetamine (MA) and amphetamine (A) was developed.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),min,9,206451,DB00182,Amphetamine
,9021435,Cmax,"After application of a single oral dose of 5 mg selegiline the Cmax values of DMS reached 5-6 ng/ml, of MA 6-7 ng/ml and of A about 2 ng/ml.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [ml],5-6,206452,DB00182,Amphetamine
,9021435,Cmax,"After application of a single oral dose of 5 mg selegiline the Cmax values of DMS reached 5-6 ng/ml, of MA 6-7 ng/ml and of A about 2 ng/ml.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [ml],6-7,206453,DB00182,Amphetamine
,9021435,Cmax,"After application of a single oral dose of 5 mg selegiline the Cmax values of DMS reached 5-6 ng/ml, of MA 6-7 ng/ml and of A about 2 ng/ml.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [ml],2,206454,DB00182,Amphetamine
,9021435,AUC infinity,"The AUC infinity values were with DMS about 11 ng/ml x h +/- 4.5, with MA about 130 g/ml x h +/- 50 and with A about 50 ng/ml x h +/- 15.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [h·ml],11,206455,DB00182,Amphetamine
,9021435,MA,"The AUC infinity values were with DMS about 11 ng/ml x h +/- 4.5, with MA about 130 g/ml x h +/- 50 and with A about 50 ng/ml x h +/- 15.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[g] / [h·ml],130,206456,DB00182,Amphetamine
,9021435,A,"The AUC infinity values were with DMS about 11 ng/ml x h +/- 4.5, with MA about 130 g/ml x h +/- 50 and with A about 50 ng/ml x h +/- 15.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [h·ml],50,206457,DB00182,Amphetamine
,21539403,maximum observed plasma concentration (C(max)),"The mean ± SD maximum observed plasma concentration (C(max)) and area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)) of d-amphetamine following PO administration of lisdexamfetamine dimesylate were 37.6 ± 4.54 ng/mL and 719.1 ± 157.05 ng · h/mL, respectively; after IN administration, these parameters were 35.9 ± 6.49 ng/mL and 690.5 ± 157.05 ng · h/mL, respectively.","Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),[ng] / [ml],37.6,213070,DB00182,Amphetamine
,21539403,maximum observed plasma concentration (C(max)),"The mean ± SD maximum observed plasma concentration (C(max)) and area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)) of d-amphetamine following PO administration of lisdexamfetamine dimesylate were 37.6 ± 4.54 ng/mL and 719.1 ± 157.05 ng · h/mL, respectively; after IN administration, these parameters were 35.9 ± 6.49 ng/mL and 690.5 ± 157.05 ng · h/mL, respectively.","Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),[ng] / [ml],35.9,213071,DB00182,Amphetamine
,21539403,area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)),"The mean ± SD maximum observed plasma concentration (C(max)) and area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)) of d-amphetamine following PO administration of lisdexamfetamine dimesylate were 37.6 ± 4.54 ng/mL and 719.1 ± 157.05 ng · h/mL, respectively; after IN administration, these parameters were 35.9 ± 6.49 ng/mL and 690.5 ± 157.05 ng · h/mL, respectively.","Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),[h·ng] / [ml],719.1,213072,DB00182,Amphetamine
,21539403,area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)),"The mean ± SD maximum observed plasma concentration (C(max)) and area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC(last)) of d-amphetamine following PO administration of lisdexamfetamine dimesylate were 37.6 ± 4.54 ng/mL and 719.1 ± 157.05 ng · h/mL, respectively; after IN administration, these parameters were 35.9 ± 6.49 ng/mL and 690.5 ± 157.05 ng · h/mL, respectively.","Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),[h·ng] / [ml],690.5,213073,DB00182,Amphetamine
,21539403,time to reach C(max) (t(max)),PO and IN administration demonstrated similar median time to reach C(max) (t(max)) for d-amphetamine: 5 hours for PO administration versus 4 hours for IN administration.,"Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),h,5,213074,DB00182,Amphetamine
,21539403,time to reach C(max) (t(max)),PO and IN administration demonstrated similar median time to reach C(max) (t(max)) for d-amphetamine: 5 hours for PO administration versus 4 hours for IN administration.,"Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),h,4,213075,DB00182,Amphetamine
,21539403,elimination half-life (t(1/2)),Mean ± SD elimination half-life (t(1/2)) values were also similar for PO (11.6 ± 2.8 hours) and IN (11.3 ± 1.8 hours) lisdexamfetamine dimesylate.,"Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),h,11.6,213076,DB00182,Amphetamine
,21539403,elimination half-life (t(1/2)),Mean ± SD elimination half-life (t(1/2)) values were also similar for PO (11.6 ± 2.8 hours) and IN (11.3 ± 1.8 hours) lisdexamfetamine dimesylate.,"Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539403/),h,11.3,213077,DB00182,Amphetamine
,26794682,tmax,"The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).",Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794682/),h,10-12,213346,DB00182,Amphetamine
,26794682,elimination (t1/2,"The aim of this study was to evaluate the abuse potential of dasotraline, a novel dopamine and norepinephrine reuptake inhibitor with slow absorption (tmax, 10-12h) and elimination (t1/2=47-77 h) that is in development for the treatment of attention deficit hyperactivity disorder (ADHD).",Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26794682/),h,47-77,213347,DB00182,Amphetamine
,7910126,Maximal plasma concentrations,Maximal plasma concentrations of cathinone (127 +/- 53 [SD] ng/ml) were attained after 127 +/- 30 minutes.,Pharmacodynamics and pharmacokinetics of khat: a controlled study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910126/),[ng] / [ml],127,214516,DB00182,Amphetamine
,7910126,area under the plasma concentration-time curve from 0 to 9 hours,"The area under the plasma concentration-time curve from 0 to 9 hours was 415 +/- 207 ng/ml.hr, and the terminal elimination half-life was 260 +/- 102 minutes.",Pharmacodynamics and pharmacokinetics of khat: a controlled study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910126/),[ng] / [h·ml],415,214517,DB00182,Amphetamine
,7910126,terminal elimination half-life,"The area under the plasma concentration-time curve from 0 to 9 hours was 415 +/- 207 ng/ml.hr, and the terminal elimination half-life was 260 +/- 102 minutes.",Pharmacodynamics and pharmacokinetics of khat: a controlled study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910126/),min,260,214518,DB00182,Amphetamine
,16715499,binding potential (BP),"The binding potential (BP) calculated by the simplified reference tissue model was 3-fold higher than that measured with [11C]-(-)-NPA (2.14 +/- 0.50 vs. 0.66 +/- 0.01, respectively).",In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715499/),,2.14,215143,DB00182,Amphetamine
,16715499,binding potential (BP),"The binding potential (BP) calculated by the simplified reference tissue model was 3-fold higher than that measured with [11C]-(-)-NPA (2.14 +/- 0.50 vs. 0.66 +/- 0.01, respectively).",In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715499/),,0.66,215144,DB00182,Amphetamine
,27206266,elimination half-life,The elimination half-life for mephedrone was 2.15 h and 7.89 h for MDMA.,Human Pharmacology of Mephedrone in Comparison with MDMA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27206266/),h,2.15,216678,DB00182,Amphetamine
,27206266,elimination half-life,The elimination half-life for mephedrone was 2.15 h and 7.89 h for MDMA.,Human Pharmacology of Mephedrone in Comparison with MDMA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27206266/),h,7.89,216679,DB00182,Amphetamine
,15777777,C(max) for,"The C(max) for C75 of 2.6+/-1.5 microM was reached within 1-4 h after intraperitoneal administration at 30 mg/kg, a drug level that causes complete blockade of food intake.",Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777777/),μM,2.6,219804,DB00182,Amphetamine
,15777777,IC50,"However, this concentration is substantially lower than the effective concentration used to inhibit rat fatty acid synthase enzyme activity in vitro (IC50: approximately 200 microM) and hypothalamic enzyme activity was found not to be inhibited by intraperitoneal administration of C75 at 30 mg/kg.",Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15777777/),μM,200,219805,DB00182,Amphetamine
,12208028,peak concentration,"Resultant plasma concentrations varied from 21 to 295 ng/ml, with an average peak concentration of 178 ng/ml observed between 2 and 4h after administration.","Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12208028/),[ng] / [ml],178,221640,DB00182,Amphetamine
,1484108,maximum concentrations,"Average maximum concentrations were 57.5 and 6.3 ng/ml for S- and R-tranylcypromine, respectively.",Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484108/),[ng] / [ml],57.5,221654,DB00182,Amphetamine
,1484108,maximum concentrations,"Average maximum concentrations were 57.5 and 6.3 ng/ml for S- and R-tranylcypromine, respectively.",Enantiospecific high-performance liquid chromatographic assay with fluorescence detection for the monoamine oxidase inhibitor tranylcypromine and its applicability in pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1484108/),[ng] / [ml],6.3,221655,DB00182,Amphetamine
,28828691,half-life,Dihydro-mephedrone represented 10% of the amount of mephedrone in plasma and N-succinyl-nor-mephedrone was the metabolite eliminated with the longer half-life of 8.2 h.,Pharmacokinetics of Mephedrone and Its Metabolites in Human by LC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828691/),h,8.2,222184,DB00182,Amphetamine
,1362938,elimination half-life,The average elimination half-life was 10.1 hr (range of 6.4-15.1 hr).,Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362938/),h,10.1,225169,DB00182,Amphetamine
,8001591,Kel,"The calculated Kel for mefenorex after the higher dose was in the range of 0.191-0.272 h-1, with a biological half life (t1/2) of 3.98-2.55 h, depending on the method of calculation used.",Urinary excretion and metabolism of orally administered mefenorex. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001591/),1/[h],0.191-0.272,226042,DB00182,Amphetamine
,8001591,biological half life (t1/2),"The calculated Kel for mefenorex after the higher dose was in the range of 0.191-0.272 h-1, with a biological half life (t1/2) of 3.98-2.55 h, depending on the method of calculation used.",Urinary excretion and metabolism of orally administered mefenorex. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001591/),h,3.98-2.55,226043,DB00182,Amphetamine
,8001591,Kel,The elimination of amphetamine was much slower with a Kel ranging from 0.039-0.073 h-1 and a t1/2 from 9.5-17.8 h.,Urinary excretion and metabolism of orally administered mefenorex. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001591/),1/[h],0.039-0.073,226044,DB00182,Amphetamine
,8001591,t1/2,The elimination of amphetamine was much slower with a Kel ranging from 0.039-0.073 h-1 and a t1/2 from 9.5-17.8 h.,Urinary excretion and metabolism of orally administered mefenorex. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001591/),h,9.5-17.8,226045,DB00182,Amphetamine
,8001591,rate constant,"Depending on the dose administered, the rate constant of metabolite formation was 0.129 and 0.685 h-1 for low and high doses, respectively.",Urinary excretion and metabolism of orally administered mefenorex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001591/),1/[h],0.129,226046,DB00182,Amphetamine
,8001591,rate constant,"Depending on the dose administered, the rate constant of metabolite formation was 0.129 and 0.685 h-1 for low and high doses, respectively.",Urinary excretion and metabolism of orally administered mefenorex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001591/),1/[h],0.685,226047,DB00182,Amphetamine
,8001591,Urinary excretion,Urinary excretion of Rondimen amounted to 11.9% within 72 h after administration.,Urinary excretion and metabolism of orally administered mefenorex. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8001591/),%,11.9,226048,DB00182,Amphetamine
,18757185,K(iz),"BL-1020 displayed strong DA and serotonin (5HT) receptor inhibition (D(2L)K(iz)=0.066 nM, D(2S)K(i)=0.062 nM, 5-HT(2A)K(i)=0.21 nM).","BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757185/),nM,0.066,227899,DB00182,Amphetamine
,18757185,K(i),"BL-1020 displayed strong DA and serotonin (5HT) receptor inhibition (D(2L)K(iz)=0.066 nM, D(2S)K(i)=0.062 nM, 5-HT(2A)K(i)=0.21 nM).","BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757185/),nM,0.062,227900,DB00182,Amphetamine
,18757185,K(i),"BL-1020 displayed strong DA and serotonin (5HT) receptor inhibition (D(2L)K(iz)=0.066 nM, D(2S)K(i)=0.062 nM, 5-HT(2A)K(i)=0.21 nM).","BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18757185/),nM,0.21,227901,DB00182,Amphetamine
,17474141,flow rate,"The DIB-derivatives of MDMA, MDA and the internal standard, 1-methyl-3-phenylpropylamine (MPPA), were isocratically separated on an ODS column using a mixture of 50 mm phosphate buffer (pH 7.0)-acetonitrile-methanol-2-propanol (50:45:5:2, v/v/v/v %) as an eluent at a flow rate of 1.5 mL/min.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ml] / [min],1.5,228860,DB00182,Amphetamine
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ng] / [ml],1.2,228861,DB00182,Amphetamine
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),,4.2,228862,DB00182,Amphetamine
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ng] / [ml],1.3,228863,DB00182,Amphetamine
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ng] / [ml],4.8,228864,DB00182,Amphetamine
∼,25019201,tmax,"The tmax is ∼ 2 h post-dose, and the plasma t1/2 is ∼ 4 - 6 h irrespective of the dose.",A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019201/),h,2,231162,DB00182,Amphetamine
,25019201,plasma t1/2,"The tmax is ∼ 2 h post-dose, and the plasma t1/2 is ∼ 4 - 6 h irrespective of the dose.",A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019201/),h,4 - 6,231163,DB00182,Amphetamine
,16344836,Tmax,"Tmax was 4.2 and 4.3 hours for d-amphetamine to l-amphetamine, respectively.",Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16344836/),h,4.2,232028,DB00182,Amphetamine
,16344836,Tmax,"Tmax was 4.2 and 4.3 hours for d-amphetamine to l-amphetamine, respectively.",Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16344836/),h,4.3,232029,DB00182,Amphetamine
,16344836,Tmax,"In Study B, for d- and l-amphetamine, statistically significant differences were observed for AUC0-t, AUC0-inf, and Cmax between all doses; there was a linear relationship between pharmacokinetic variables and dose and Tmax was similar for each isomer (range: 4.5-5.3 hours) with all given MAS XR doses.",Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16344836/),h,4.5-5.3,232030,DB00182,Amphetamine
,19428944,maximum plasma concentration,"PMMA maximum plasma concentration of 4014+/-1122ng/mL was reached 30min after dosing, whereas the appearance of metabolites was rather delayed.",Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),[ng] / [ml],4014,232878,DB00182,Amphetamine
,19428944,half-life,"The disposition of PMMA was characterized by its approximate half-life of 1.0h, volume of distribution of 6.4L/kg and plasma clearance of 4.4L/h.",Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),h,1.0,232879,DB00182,Amphetamine
,19428944,volume of distribution,"The disposition of PMMA was characterized by its approximate half-life of 1.0h, volume of distribution of 6.4L/kg and plasma clearance of 4.4L/h.",Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),[l] / [kg],6.4,232880,DB00182,Amphetamine
,19428944,plasma clearance,"The disposition of PMMA was characterized by its approximate half-life of 1.0h, volume of distribution of 6.4L/kg and plasma clearance of 4.4L/h.",Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),[l] / [h],4.4,232881,DB00182,Amphetamine
,19428944,c(max),"PMMA tissue concentration exceeded plasma and the highest one was found in the lungs (c(max) 42,988+/-10,223ng/g).",Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),[ng] / [g],"42,988",232882,DB00182,Amphetamine
,19428944,maximum brain/plasma ratio,The maximum brain/plasma ratio value of PMMA (15.8) and PMA (11.8) was reached after 8h of observation.,Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),,15.8,232883,DB00182,Amphetamine
,19428944,maximum brain/plasma ratio,The maximum brain/plasma ratio value of PMMA (15.8) and PMA (11.8) was reached after 8h of observation.,Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),,11.8,232884,DB00182,Amphetamine
,18794647,metabolic ratio,"The metabolic ratio increased almost 100-fold from 0.0061 +/- 0.0056 to 0.4322 +/- 0.2848 after MDMA administration, with 67% of the subjects having a value greater than the antimode of 0.3 for assigning the poor metabolizer phenotype.","The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794647/),,0.00,233432,DB00182,Amphetamine
,18794647,metabolic ratio,"The metabolic ratio increased almost 100-fold from 0.0061 +/- 0.0056 to 0.4322 +/- 0.2848 after MDMA administration, with 67% of the subjects having a value greater than the antimode of 0.3 for assigning the poor metabolizer phenotype.","The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794647/),,0.,233433,DB00182,Amphetamine
,18794647,recovery half-life,CYP2D6 activity recovered after 10 days with a recovery half-life of 46.6 hours.,"The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18794647/),h,46.6,233434,DB00182,Amphetamine
,12906896,lambda(ex),"A chiral stationary protein phase (chiral-CBH) was used for the stereoselective determination of MDE, HME and MDA in a single HPLC run using sodium dihydrogenphosphate, ethylendiaminetetraacetic acid disodium salt and isopropanol as the mobile phase (pH 6.44) and fluorimetric detection (lambda(ex) 286 nm, lambda(em) 322 nm).","Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906896/),,286,233990,DB00182,Amphetamine
,12906896,lambda(em),"A chiral stationary protein phase (chiral-CBH) was used for the stereoselective determination of MDE, HME and MDA in a single HPLC run using sodium dihydrogenphosphate, ethylendiaminetetraacetic acid disodium salt and isopropanol as the mobile phase (pH 6.44) and fluorimetric detection (lambda(ex) 286 nm, lambda(em) 322 nm).","Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906896/),,322,233991,DB00182,Amphetamine
>,12906896,recovery rates,The method showed high recovery rates (>95%) and limits of quantitation for MDE and MDA of 5 ng/ml and for HME of 10 ng/ml.,"Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906896/),%,95,233992,DB00182,Amphetamine
,12906896,ratio R:S,"The plasma concentrations of (R)-MDE exceeded those of the S-enantiomer (ratio R:S of the area under the curve, 3.1) and the plasma half time of (R)-MDE was longer than that of (S)-MDE (7.9 vs. 4.0 h).","Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906896/),,3.1,233993,DB00182,Amphetamine
,12906896,plasma half time,"The plasma concentrations of (R)-MDE exceeded those of the S-enantiomer (ratio R:S of the area under the curve, 3.1) and the plasma half time of (R)-MDE was longer than that of (S)-MDE (7.9 vs. 4.0 h).","Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906896/),h,7.9,233994,DB00182,Amphetamine
,12906896,plasma half time,"The plasma concentrations of (R)-MDE exceeded those of the S-enantiomer (ratio R:S of the area under the curve, 3.1) and the plasma half time of (R)-MDE was longer than that of (S)-MDE (7.9 vs. 4.0 h).","Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906896/),h,4.0,233995,DB00182,Amphetamine
,19800446,K(D),"These studies examined the in vivo pharmacokinetics and efficacy of five anti-methamphetamine monoclonal antibodies (mAbs, K(D) values from 11 to 250 nM) in rats.",Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19800446/),nM,11 to 250,240971,DB00182,Amphetamine
,19800446,t(1/2),"While no substantive differences in mAb systemic clearance (t(1/2)=6.1-6.9 days) were found, in vivo function was significantly reduced within 1-3 days for four of the five mAbs.",Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19800446/),d,6.1-6.9,240972,DB00182,Amphetamine
,26295148,zeta potential,OLA-LNC were successfully developed with a particle size of 142 ± 4 nm and a zeta potential of -19.6 ± 0.6 mV.,Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26295148/),mv,-19.6,242212,DB00182,Amphetamine
,26295148,relative bioavailability,"Higher olanzapine concentrations and AUC(0-12 h) were found in plasma and tissues evaluated after the administration of OLA-LNC compared to the drug in the free form, resulting in a relative bioavailability of 226.7% in the plasma.",Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26295148/),%,226.7,242213,DB00182,Amphetamine
,7636721,peak plasma,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),μM,1.7,246902,DB00182,Amphetamine
,7636721,peak plasma,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,36,246903,DB00182,Amphetamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),μM,2.9,246904,DB00182,Amphetamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,73,246905,DB00182,Amphetamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,25,246906,DB00182,Amphetamine
,7636721,tissue levels,"After one or three doses of 5 mg/kg, peak plasma and tissue levels of AMPH were 1.7 +/- 0.2 and 2.9 +/- 0.3 microM in plasma, 36 +/- 6 and 73 +/- 10 in substantia nigra and 25 +/- 4 and 50 +/- 8 in caudate/putamen, respectively.","Amphetamine levels in brain microdialysate, caudate/putamen, substantia nigra and plasma after dosage that produces either behavioral or neurotoxic effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636721/),,50,246907,DB00182,Amphetamine
,23122405,gradient flow rate,The whole analysis lasted for 10.5min and the gradient flow rate was 0.25mL/min constantly.,Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),[ml] / [min],0.25,248244,DB00182,Amphetamine
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,354.0,248245,DB00182,Amphetamine
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,191.8,248246,DB00182,Amphetamine
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,356.0,248247,DB00182,Amphetamine
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,148.7,248248,DB00182,Amphetamine
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,358.0,248249,DB00182,Amphetamine
,23122405,m/z ratios,"The results were that the m/z ratios of monitored precursor ions and product ions of PPTA, M1 and M6 were 354.0→191.8, 356.0→148.7 and 358.0→148.7, respectively.",Determination of piperphentonamine and metabolites M1 and M6 in human plasma and urine by LC/MS/MS and its application in a pharmacokinetics study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23122405/),,148.7,248250,DB00182,Amphetamine
,712637,t1/2,"After intraperitoneal administration of a single dose of [3H]AMPH, tissue [3H]AMPH levels increased rapidly to a maximum within 15 to 20 min of administration and then declined biphasically [(t1/2 = 0.5--0.9 hr for the distribution phase (alpha) and 5--9 hr for the elimination phase (beta)].",Metabolism of amphetamine after acute and chronic administration to the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712637/),h,0.5,248895,DB00182,Amphetamine
,712637,t1/2,"After intraperitoneal administration of a single dose of [3H]AMPH, tissue [3H]AMPH levels increased rapidly to a maximum within 15 to 20 min of administration and then declined biphasically [(t1/2 = 0.5--0.9 hr for the distribution phase (alpha) and 5--9 hr for the elimination phase (beta)].",Metabolism of amphetamine after acute and chronic administration to the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712637/),h,0.9,248896,DB00182,Amphetamine
,712637,t1/2,"After intraperitoneal administration of a single dose of [3H]AMPH, tissue [3H]AMPH levels increased rapidly to a maximum within 15 to 20 min of administration and then declined biphasically [(t1/2 = 0.5--0.9 hr for the distribution phase (alpha) and 5--9 hr for the elimination phase (beta)].",Metabolism of amphetamine after acute and chronic administration to the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712637/),h,5,248897,DB00182,Amphetamine
,712637,t1/2,"Tissue [3H]POHA levels and liver [3H] POHAG levels also increased rapidly and then declined exponentially (t1/2 = 4--10 hr for POHA), while tissue [3H]POHNOR increased gradually and declined with a half-life of 18 to 24 hr.",Metabolism of amphetamine after acute and chronic administration to the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712637/),h,4--10,248898,DB00182,Amphetamine
,712637,half-life,"Tissue [3H]POHA levels and liver [3H] POHAG levels also increased rapidly and then declined exponentially (t1/2 = 4--10 hr for POHA), while tissue [3H]POHNOR increased gradually and declined with a half-life of 18 to 24 hr.",Metabolism of amphetamine after acute and chronic administration to the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/712637/),h,18 to 24,248899,DB00182,Amphetamine
,17724664,Elimination half-life,Elimination half-life was increased for MDMA (2.4 vs. 4.9 h) and MDA (1.8 vs.,"Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724664/),h,2.4,251481,DB00182,Amphetamine
,17724664,Elimination half-life,Elimination half-life was increased for MDMA (2.4 vs. 4.9 h) and MDA (1.8 vs.,"Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724664/),h,4.9,251482,DB00182,Amphetamine
,17724664,Elimination half-life,Elimination half-life was increased for MDMA (2.4 vs. 4.9 h) and MDA (1.8 vs.,"Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17724664/),,1.8,251483,DB00182,Amphetamine
,17519073,time to maximum observed plasma concentration (Tmax),Median time to maximum observed plasma concentration (Tmax) values for d-amphetamine and l-amphetamine were 8.0 h for triple-bead MAS and 10.0 h for MAS XR + MAS IR.,Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519073/),h,8.0,252218,DB00182,Amphetamine
,17519073,time to maximum observed plasma concentration (Tmax),Median time to maximum observed plasma concentration (Tmax) values for d-amphetamine and l-amphetamine were 8.0 h for triple-bead MAS and 10.0 h for MAS XR + MAS IR.,Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17519073/),h,10.0,252219,DB00182,Amphetamine
,18065502,AUC,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ng] / [h·ml],90.7,258469,DB00182,Amphetamine
,18065502,AUC,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ng] / [h·ml],57.4,258470,DB00182,Amphetamine
,18065502,clearance,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ml] / [min],4.6,258471,DB00182,Amphetamine
,18065502,clearance,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ml] / [min],7.3,258472,DB00182,Amphetamine
,18065502,elimination half-life,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),min,12.5,258473,DB00182,Amphetamine
,18065502,elimination half-life,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),min,6.6,258474,DB00182,Amphetamine
,18065502,K(i),Selegiline preincubation increased inhibition in microsomes (3.7-fold) and CYP2A6 (14.8-fold); the K(i) for CYP2A6 was 4.2 muM.,Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),muM,4.2,258475,DB00182,Amphetamine
,18065502,K(i),"Selegiline dose- and time-dependently inhibited nicotine metabolism by CYP2A6 (K(i) = 15.6 +/- 2.7 muM; k(inact) = 0.34 +/- 0.04 min(-1)), and the inhibition was irreversible in the presence of NADPH, indicating that it is a mechanism-based inhibitor of CYP2A6.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),muM,15.6,258476,DB00182,Amphetamine
,18065502,k(inact),"Selegiline dose- and time-dependently inhibited nicotine metabolism by CYP2A6 (K(i) = 15.6 +/- 2.7 muM; k(inact) = 0.34 +/- 0.04 min(-1)), and the inhibition was irreversible in the presence of NADPH, indicating that it is a mechanism-based inhibitor of CYP2A6.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),1/[min],0.34,258477,DB00182,Amphetamine
,25948577,milk/maternal plasma concentration ratio,The transfer of rac-amphetamine to the breast milk was extensive (mean milk/maternal plasma concentration ratio approximately 3).,Narcolepsy Treated with Racemic Amphetamine during Pregnancy and Breastfeeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25948577/),,3,258802,DB00182,Amphetamine
,19164498,pseudo-steady state levels,MDMA (100 mg) was given orally while blood alcohol concentration was maintained at pseudo-steady state levels of approximately 0.6 per thousand for 3 h by a 10% intravenous ethanol clamp.,Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19164498/),1/[thousand],0.6,259565,DB00182,Amphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5370,262206,DB00182,Amphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5246,262207,DB00182,Amphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.43,262208,DB00182,Amphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.87,262209,DB00182,Amphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.23,262210,DB00182,Amphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.11,262211,DB00182,Amphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],677.9,262212,DB00182,Amphetamine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],466.9,262213,DB00182,Amphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,207",262214,DB00182,Amphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,688",262215,DB00182,Amphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],34.85,262216,DB00182,Amphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],37.27,262217,DB00182,Amphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],92.07,262218,DB00182,Amphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],93.04,262219,DB00182,Amphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1428,262220,DB00182,Amphetamine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1499,262221,DB00182,Amphetamine
,24333768,plasma Cmax,Pharmacokinetic analysis revealed that a 24-hour intravenous infusion of methamphetamine at a dose of 0.500 mg/kg/h produced a plasma Cmax value of 25.9 ng/ml and a total exposure of 544 ng/ml over a 32 hour time frame.,Administration of low dose methamphetamine 12 h after a severe traumatic brain injury prevents neurological dysfunction and cognitive impairment in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333768/),[ng] / [ml],25.9,262714,DB00182,Amphetamine
,24333768,total exposure,Pharmacokinetic analysis revealed that a 24-hour intravenous infusion of methamphetamine at a dose of 0.500 mg/kg/h produced a plasma Cmax value of 25.9 ng/ml and a total exposure of 544 ng/ml over a 32 hour time frame.,Administration of low dose methamphetamine 12 h after a severe traumatic brain injury prevents neurological dysfunction and cognitive impairment in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333768/),[ng] / [ml],544,262715,DB00182,Amphetamine
,16413604,elimination half-life,"The elimination half-life of methamphetamine was approximately 12 h, and selegiline did not alter clearance of methamphetamine.",A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413604/),h,12,265657,DB00182,Amphetamine
,23471370,OF/P ratios,Median (range) OF/P ratios were 5.6 (0.1-52.3) for MDMA and 3.7 (0.7-24.3) for MDA.,"Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,5.6,267157,DB00182,Amphetamine
,23471370,OF/P ratios,Median (range) OF/P ratios were 5.6 (0.1-52.3) for MDMA and 3.7 (0.7-24.3) for MDA.,"Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,3.7,267158,DB00182,Amphetamine
,23471370,OF/P,"Median OF/P ratios were significantly higher following high dose administration: MDMA low = 5.2 (0.1-40.4), high = 6.0 (0.4-52.3, p < 0.05); MDA low = 3.3 (0.7-17.1), high = 4.1 (0.9-24.3, p < 0.001).","Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,5,267159,DB00182,Amphetamine
,23471370,OF/P,"Median OF/P ratios were significantly higher following high dose administration: MDMA low = 5.2 (0.1-40.4), high = 6.0 (0.4-52.3, p < 0.05); MDA low = 3.3 (0.7-17.1), high = 4.1 (0.9-24.3, p < 0.001).","Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,6,267160,DB00182,Amphetamine
,23471370,OF/P,"Median OF/P ratios were significantly higher following high dose administration: MDMA low = 5.2 (0.1-40.4), high = 6.0 (0.4-52.3, p < 0.05); MDA low = 3.3 (0.7-17.1), high = 4.1 (0.9-24.3, p < 0.001).","Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,3,267161,DB00182,Amphetamine
,23471370,OF/P,"Median OF/P ratios were significantly higher following high dose administration: MDMA low = 5.2 (0.1-40.4), high = 6.0 (0.4-52.3, p < 0.05); MDA low = 3.3 (0.7-17.1), high = 4.1 (0.9-24.3, p < 0.001).","Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471370/),,4,267162,DB00182,Amphetamine
,9373724,ratio of formation-absorption rate constant,"Compartmental analysis indicates that the ratio of formation-absorption rate constant for the selegiline to N-desmethylselegiline pathway decreases from 1.57 +/- 1.04 for the first pulse to 0.61 +/- 0.54 for the second pulse of the pulsatile delivery system, suggesting that the upper portion of the GI tract has a greater capacity to convert selegiline to N-desmethylselegiline than the lower GI tract.",Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373724/),,1.57,269039,DB00182,Amphetamine
,9373724,ratio of formation-absorption rate constant,"Compartmental analysis indicates that the ratio of formation-absorption rate constant for the selegiline to N-desmethylselegiline pathway decreases from 1.57 +/- 1.04 for the first pulse to 0.61 +/- 0.54 for the second pulse of the pulsatile delivery system, suggesting that the upper portion of the GI tract has a greater capacity to convert selegiline to N-desmethylselegiline than the lower GI tract.",Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373724/),,0.61,269040,DB00182,Amphetamine
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],"21,470",270748,DB00182,Amphetamine
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],2229,270749,DB00182,Amphetamine
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],"20,793",270750,DB00182,Amphetamine
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],876,270751,DB00182,Amphetamine
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,13.9,270752,DB00182,Amphetamine
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,23.0,270753,DB00182,Amphetamine
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,9.2,270754,DB00182,Amphetamine
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,23.3,270755,DB00182,Amphetamine
,19874650,total urinary excretion,"In the first 24 h, 30.2-34.3% total urinary excretion occurred.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),%,30.2-34.3,270756,DB00182,Amphetamine
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,136,271167,DB00182,Amphetamine
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,144,271168,DB00182,Amphetamine
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,90,271169,DB00182,Amphetamine
,21456632,C(max),"The mean ± SD C(max) of MDMA was 188.8 ± 16.7 ng/mL, with a time to reach C(max) (t(max)) of 2.0 ± 0.4 hours and an AUC from 0 to 25 hours of 2645.2 ± 170.9 mg · h/mL.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),[ng] / [ml],188.8,273634,DB00182,Amphetamine
,21456632,time to reach C(max) (t(max)),"The mean ± SD C(max) of MDMA was 188.8 ± 16.7 ng/mL, with a time to reach C(max) (t(max)) of 2.0 ± 0.4 hours and an AUC from 0 to 25 hours of 2645.2 ± 170.9 mg · h/mL.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),h,2.0,273635,DB00182,Amphetamine
,21456632,AUC from 0 to 25 hours,"The mean ± SD C(max) of MDMA was 188.8 ± 16.7 ng/mL, with a time to reach C(max) (t(max)) of 2.0 ± 0.4 hours and an AUC from 0 to 25 hours of 2645.2 ± 170.9 mg · h/mL.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),[h·mg] / [ml],2645.2,273636,DB00182,Amphetamine
,21456632,urinary recovery,The urinary recovery of the dextromethorphan dose as dextromethorphan and its main metabolites was 25.4 ± 8.9% with no MDMA pretreatment versus 6.6 ± 1.1% after 1.5 mg/kg of MDMA (p = 0.0001).,"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),%,25.4,273637,DB00182,Amphetamine
,21456632,urinary recovery,The urinary recovery of the dextromethorphan dose as dextromethorphan and its main metabolites was 25.4 ± 8.9% with no MDMA pretreatment versus 6.6 ± 1.1% after 1.5 mg/kg of MDMA (p = 0.0001).,"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),%,6.6,273638,DB00182,Amphetamine
,21456632,metabolic ratio (MR),"The metabolic ratio (MR) increased almost 60-fold from 0.018 ± 0.028 to 0.998 ± 0.932 after MDMA administration, with 100% of the subjects having a value greater than the antimode of 0.3 that signified the poor-metabolizer phenotype.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),,0.018,273639,DB00182,Amphetamine
,21456632,metabolic ratio (MR),"The metabolic ratio (MR) increased almost 60-fold from 0.018 ± 0.028 to 0.998 ± 0.932 after MDMA administration, with 100% of the subjects having a value greater than the antimode of 0.3 that signified the poor-metabolizer phenotype.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),,0.998,273640,DB00182,Amphetamine
,21456632,recovery half-life,"CYP2D6 activity recovered after 10 days to 90% of baseline activity, with a recovery half-life of 36.6 ± 22.9 hours.","Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),h,36.6,273641,DB00182,Amphetamine
,21456632,recovery half-life,Male subjects showed a shorter recovery half-life (27.6 ± 25.1 hours).,"Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21456632/),h,27.6,273642,DB00182,Amphetamine
